Name	CAS #	SMILES	VDss	CL	fu	MRT (h)	terminal  t1/2	Reference	Comments 	Notes	Year of first disclosure	MW	HBA	HBD	TPSA_NO	RotBondCount	moka_ionState7.4	MoKa.LogP	MoKa.LogD7.4	datasplit
Dopamine	51-61-6	c1(cc(c(O)cc1)O)CCN	0.74	65.9	0.87	0.19	0.42	Data digitized from Fig. 1 P.-0. JARNBEG, L. BENGTSSOJN, E KSTRANaD, B. HAMBERCER Dopamine Infusion in Man. Plasma Catecholamine Levels and Pharmacokinetics. Acta anaesth. scand. 1981, 25, 328-331.//ppb: Gunhild Franksson and Erik Änggård The Plasma Protein Binding of Amphetamine,  Catecholamines and  Related Compounds. Acta Pharmacol. Toxicol.1970, 28,  209-214.	N=8 for 2 and 5 ug/kg/min, 30' infusion. Data digitized from Fig.1		1910	153.18	3	3	66.5	2	cationic	0.56	-2.0	train
Dihydroergosine	7288-61-1	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C)NC(=O)[C@@H]4C[C@@H]5c6cccc7c6c(c[nH]7)C[C@H]5N(C4)C)O	4.02	12.85		5.01	8.84	Cvelbar, Polona; Culig, J.; Kopitar, Z.; Lenardic, A.; Urbancic-Smerkolj, Janja; Zorz, M. Bioavailability of dihydroergosine in healthy volunteers. Proc. - 3rd Eur. Congr. Biopharm. Pharmacokinet., 1987, Volume 3, 147-53	N=8, 0.75 mg dose, 75 kg median weight. Clearance recalculated from dose and AUC. Erroneously reported as 0.96 mL/min when it should have been 0.96 L/min.	Nice example of enterohepatic recirculation.	1943	549.66	10	3	118.2	4	cationic	3.7	3.2	test
Avarofloxacin	878592-87-1	COc1c2c(cc(c1N3CCC/C(=C(/CN)\F)/C3)F)c(=O)c(cn2C4CC4)C(=O)O	1.13	0.78	0.34	24.21	19.64	J. Michael Davenport, Paul Covington, Mark Gotfried, Matthew Medlock, Prapoch Watanalumlerd, Gail McIntyre, Lisa Turner, and June Almenoff. Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2//ppb: G Eichenbaum, MK Pugsley, DJ Gallacher, R Towart, G McIntyre, U Shukla, JM Davenport, HR Lu, J Rohrbacher, and V Hillsamer. Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2. Br. J. Clin. Pharmacol. 2012, 166, 1694-1707.	"JNJ-Q2. Acorafloxacin. Data digitized from plot reported. 75 mg dose chosen as ""bracketed by the range 15-150 mg. Generally linear PK. 70 kg average weight assumed. 90-minute infusion. AUC 0-inf reported as 25 ug.h.mL. Calculated 22.9 ug.h.mL. 9% difference. ppb midpoint of range: 62% at 2 ug/mL and 70% at 20 ug/mL."		2006	419.42	7	2	97.8	5	zwitterionic	2.8	0.44	train
SNS-032	345627-80-7	N1CCC(CC1)C(=O)Nc1sc(cn1)SCc1oc(cn1)C(C)(C)C	5.14	13.0		7.13	9.3	Phase I and Pharmacologic Study of SNS-032, a Potentand Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma Wei-Gang Tong, Rong Chen, William Plunkett, David Siegel, Rajni Sinha, R. Donald Harvey, Ashraf Z. Badros, Leslie Popplewell, Steven Coutre, Judith A. Fox, Kristi Mahadocon, Tianling Chen, Peggy Kegley, Ute Hoch, and William G. Wierda. J Clin Oncol 201. 28:3015-3022.	BMS 387032. Weighted average across 32 patients. Dose range 15 to 100 mg/m2. 		2001	380.53	6	2	80.3	5	cationic	2.0	0.64	train
Felodipine	72509-76-3	CCOC(=O)C1=C(C)NC(=C(C1c2cccc(Cl)c2Cl)C(=O)OC)C	4.4	11.0	0.0035999999999999	6.7	10.0	Edgar B, Regardh CG, Johnsson G, Johansson L, Lundborg P, Lofberg I, and Ronn O (1985) Felodipine kinetics in healthy men.  Clin. Pharmacol. Ther. 38: 205-211.	VDss calculated from compartmental parameters provided in the reference by Edgar, et al., 1985.		1980	384.25	5	1	64.6	6	neutral	4.2	4.2	train
Eptaloprost	90693-76-8	[H]OC(CCCOCC=C1C[C@H]2C[C@H]([C@@H](C#C[C@H]([C@@H](C)CC#CCC)O[H])[C@H]2C1)O[H])=O	2.4	66.2		0.59	0.41	Hildebrand M, Inter-species Extrapolation of Pharmacokinetic Data of Three Procyclin-Mimetics, Prostaglandins, 1994, 48, 297-312.	 t1/2=0.693/kel. Data reported and used for allometric scaling were taken from other publications by the same author.		1984	402.52	5	3	87.0	15	anionic	3.0	0.22	test
Methylnaltrexone	73232-52-7	C[N+]1(CC2CC2)CC[C@]34[C@H]5Oc6c(O)ccc(C[C@@H]1[C@]3(O)CCC5=O)c46	2.6	22.0	0.87	2.0	2.5	Yuan CS, Doshan H, Charney MR, O'Connor M, Karrison T, Maleckar SA, Israel RJ, and Moss J (2005) Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.  J. Clin. Pharmacol.  45: 538-546. ppb: Reported by PDR as The fraction of methylnaltrexone bromide bound to human plasma proteins is 11.0% to 15.3%, as determined by equilibrium dialysis. Aceessed December 2014. http://www.pdr3d.com/detail.php?c=7437#section-13	CAS # for methyl naltrexone bromide. CAS for parent 83387-25-1. SMILES entered for parent without bromide anion.		1979	356.44	5	2	66.8	2	neutral	-2.7	-1.4	train
Artesunate	88495-63-0	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	15.0	1070.0	0.25	0.32	0.22	Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul, W, Ruangveerayuth R, and WhiteNJ (2006) The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.    Eur. J. Clin. Pharmacol.  62: 1003-1009.  Li Q, Xie LH, Haeberle A, Zhang J, and Weina P (2006) The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans.  Am. J. Trop. Med. Hyg. 75: 817-826.			1982	384.42	8	1	100.5	5	neutral	3.0	2.9	train
Apalcillin	63469-19-2	[H]N(C([C@@H](c1ccccc1)N([H])C(c1cnc2cccnc2c1O[H])=O)=O)[C@@H]1C2N(C1=O)[C@@H](C(=O)O[H])C(C)(C)S2	0.16	1.9	0.1	1.4	1.2	Busch von U., Heinzel g., Seyfarth H., Mielenz H. Arzneim.-Forsch. 1982, 32, 1131-1135.  Investigation of the pharmacokinetics of apalcillin in man.	Data digitized is reported only for 1 subject (subject 3) AUC reported for individual subject in close agreement with reported clearance and AUC as well as for t1/2. N=7 and 70 kg average weight assumed. Subject # 3 in the middle of range and considered representative of cohort. Protein binding reported as approximately 90%.		1977	521.55	11	4	161.8	8	anionic	1.8	-1.6	train
Menogaril	71628-96-1	c12c3c([C@@]4(O[C@@H](O3)[C@@H](O)[C@@H]([C@@H]4O)N(C)C)C)cc(c1C(c1c(c3[C@@H](C[C@@](Cc3cc1C2=O)(C)O)OC)O)=O)O	9.14	11.61		13.13	13.22	Merrill J. Egorin, David A. Van Echo, Margaret Y. Whitacre, Alan Forrest, Lawrence M. Sigman, Kathrin L. Engisch, and Joseph Aisner (1986). Human Pharmacokinetics, Excretion, and Metabolism of the Anthracycline Antibiotic Menogaril (7-OMEN, NSC 269148) and Their Correlation with Clinical Toxicities. CANCER RESEARCH 46, 1513-1520	NSC 269148. Menogarol. 7-OMEN. Average clearance and VDss as reported by authors. 1.73 m2/70 factor used. Overall 24 stuides at different doses (infusion). MRT from clearance and VDss.	From paper cited: In humans, as in rabbits (8), neither urinary or biliary excretion of 7-OMEN and its fluorescent metabolites represented a major route of drug clearance.	1978	541.55	11	5	166.2	2	zwitterionic	1.4	-1.2	train
Cotinine	486-56-6	CN1[C@@H](CCC1=O)c2cccnc2	1.1	0.89		21.0	17.0	Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, and Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.  Klin. Wochenschr. 66(Supp 11): 5-11.  Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, and Enzell CR (1990) The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 281-287. 	VDss calculated from C vs t data obtained by digitization of the plots provided in the references.		1956	176.22	3	0	33.2	1	neutral	-0.33	-0.33	train
Ketobemidone	469-79-4	CCC(=O)C1(CCN(C)CC1)c2cccc(O)c2	0.48	9.2		0.87	2.3	Bondesson U, Arner S, Anderson P, Boreus LO, and Hartvig P (1980) Clinical pharmacokinetics and oral bioavailability of ketobemidone.  Eur. J. Clin. Pharmacol.  17: 45-50.	Calculated from reported rate micro-constants.		1946	247.33	3	1	40.5	3	cationic	1.5	0.0027	train
IDX899	1097733-15-7	c12c(ccc(c1)Cl)[nH]c(c2P(=O)(c1cc(cc(c1)/C=C/C#N)C)OC)C(=O)N	0.56	1.71		5.5	4.4	Microdose Pharmacokinetics of IDX899 and IDX989, Candidate HIV-1 Non-NucleosideReverse Transcriptase Inhibitors, Following Oral and Intravenous Administration in Healthy Male Subjects. Xiao-Jian Zhou,  R. Colin Garner,  DSc, Sheila Nicholson,  C. James Kissling,and Douglas Mayers. J Clin Pharmacol  2009, 49 (12) 1408-1416. 	GSK2248761. No structure available in SciFinder as of January 14 2012. Available in cited paper. Data digitized from figure 2. 3% difference in AUCinf with reported value. Microdose of 100 ug but PK confirmed for oral legs at pharmacologically relevant doses of 200 and 1200 mg. Iv infusion of 30' N=8, 76.6 kg average weight. 	Also reported as GSK 2248761 in SciFinder	2009	413.79	6	2	109.0	6	neutral	2.9	2.9	train
Lisdexamfetamine	608137-32-2	C[C@@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)N	0.6	17.0		0.6	1.2	Jasisnki DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. Journal of Psychopharmacology, 2009,  23, 410–418	N=9, 69.5 kg average weight. No data reported for LDX. Lisine prodrug (amide) of dexamfetamine. CAS: 51-64-9 (+)-(S)-amphetamine		2005	263.38	4	3	81.1	8	cationic	0.95	-2.1	train
Doxorubicin	23214-92-8	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	22.0	15.0	0.28	24.0	32.0	Carmaggi CM, Comparsi R, Strocchi E, Testoni F, Angelli B, and Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics.  Canc. Chemother. Pharmacol. 21: 221-228.  Piscitelli SC, Rodvold KA, Rushing DA, and Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.  Clin. Pharmacol. Ther. 53: 555-561.  Eksborg S, Ehrsson H, and Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to adriamycin.    Cancer Chemother. Pharmacol. 10: 7-10.	Adriamycin, Adriblastin.		1971	543.52	12	6	206.1	5	cationic	0.46	-2.2	test
Hydroxysafflor yellow A	78281-02-4	C1(C(=C([C@@](C(=C1C(\C=C\c1ccc(cc1)O)=O)O)(O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)=O	0.2	1.0	0.22	3.6	2.9	 Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers. Yang, Zhifu; Yang, Jing; Jia, Yanyan; Tian, Yun; Wen, Aidong  Journal of Ethnopharmacology (2009), 124, (3), 635-638. ppb: Wang, Jianming; Zou, Tian; Zhang, Yuanyuan; Fan, Ning. Study on plasma protein-​binding rate of hydroxysafflor yellow A in safflor yellow powder injection. Zhongchengyao (2011), 33(6), 947-949. Data from abstract in English.	HSYA, Safflomin A. Data digitized from figure 1. 1 hr infusion, all female chinese subjects, average weight 57.1 kg. 35, 70 and 140 mg doses. N=12 per dose group.		1981	612.53	16	12	295.4	7	neutral	-0.48	-0.51	train
Lipoic acid, S(-)-α	1077-27-6	C1CSS[C@H]1CCCCC(=O)O	0.11	13.4		0.13	0.21	Hermann, R.; Niebch, G.; Borbe, H. O.; Fieger-Bueschges, H.; Ruus, P.; Nowak, H.; Riethmueller-Winzen, H.; Peukert, M.; Blume, H. Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. European Journal of Pharmaceutical Sciences (1996), 4(3), 167-174.	200 mg (racemic) iv 4min infusion. N=12. Digitized from figure 3.  AUC differing by 12% from reported.		1956	206.33	2	1	37.3	5	anionic	2.4	0.038	train
Hydroxycamptothecin, 10-	19685-09-7	CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5ccc(cc5c4)O)O	0.22	2.23		1.63	1.67	LI Su, ZHANG Li, GUANG Zhong-zhen, ZHAN Jing, LI Yu-yan , JIANG Wen-qi. Absolute bioavailability of hydroxycamptothecin tablets in cancer patients. Chin. J. Clin. Pharmacol. 2005, 22, 46-49.(written in Chinese) 	N=8, 12 mg.m-2 dose, conversion factor 1.73m2/70kg, 30 minutes infusion. Data digitized and PK parameters calculated via PKSolver. AUC reported as 2171 ug.h.L-1 (not specified); AUS (inf) calculated as 2211 ng.h.mL-1. 2% difference.		1969	364.35	7	2	101.6	1	neutral	1.4	1.4	train
Chlordiazepoxide	58-25-3	CNC1=Nc2ccc(Cl)cc2C(=N(=O)C1)c3ccccc3	0.25	0.37	0.056	11.0	8.3	Desmond PV, Patwardhan RV, Schenker S, and Hoyumpa AM (1980) Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man.  Eur. J. Clin. Pharmacol. 18: 275-278.  Boxenbaum HG, Geitner KA, Dixon WR, Spiegel HE, Symington J, Christian R, Moore JD, Weissman L, and Kaplan SA (1977) Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HCl in healthy subjects: single-dose studies by the intravenous, intramuscular, and oral routes.  J. Pharmacokinet. Biopharm. 5: 3-23.  Desmond PV, Roberts, RK, Wood AJJ, Dunn GD, Wilkinson GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.    Br. J. Clin. Pharmacol.  9: 171-175.  			1955	299.75	4	1	53.1	2	neutral	1.4	1.4	train
Cefpirome	84957-29-9	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)[O-])C[n+]3cccc4CCCc34)\c5csc(N)n5	0.24	1.9	0.9	2.1	1.7	Nakayama I, Akieda Y, Yamaji E, Nitta Y, Ohishi M, Katagiri K, Imamura N, and Takase K (1992) Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers,  J. Clin. Pharmacol. 32: 256-266.  Tabata S, Shimura T, Maeda T, Hayashi S, Kobayashi I, and Saito A (1991) Protein binding of cefpirome sulfate in man and animals and its displacing effect on bilirubin bound to human serum albumin.    Chemotherapy  39(Suppl. 1):  109-114.			1982	514.58	11	2	153.9	7	anionic	0.7	-1.6	train
Pindolol	13523-86-9	CC(C)NCC(O)COc1cccc2[nH]ccc12	1.2	7.7	0.58	2.6	2.2	Lavene D, Weiss YA, Safar ME, Loria Y, Agorus H, Georges D, and Milliez PL (1977) Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.  J. Clin. Pharmacol. 17: 501-508.  Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists. Br. J. Clin. pharmacol. 11: 119P-120P. 	VDss calcualted from reported micro rate constants.		1966	248.32	4	3	57.3	6	cationic	1.8	0.05	train
Gallopamil	16662-47-8	c1([C@@](CCC[N@@](CCc2cc(c(OC)cc2)OC)C)(C(C)C)C#N)cc(c(OC)c(c1)OC)OC	1.75	14.3	0.07	2.04	1.8	Eichelbaum M. Pharmakokinetik und Metabolismus von. Gallopamil. Zeitschrift ftir Kardiologie 78 (Suppl. 5): 20-24, 1989.  ppB; Stieren, B.; Buehler, V.; Hege, H. G.; Hollmann, M.; Neuss, H.; Schlepper, M.; Weymann, J. Edited by Kaltenbach, Martin; Hopf, Ruediger  Gallopamil:  Pharmakol. Klin. Wirkungsprofil Kalziumantagonisten (1983), 90-96. From abstract in English.	Data digitized from plot in figure 4. 70 kg average weight assumed. 2 mg dose iv bolus. N=12. Reported AUC 29.6 ng.hr/mL. Reported clearance 1.2 L/min.		1963	484.63	7	0	73.2	15	cationic	4.3	2.8	train
Bidisomide	103810-45-3	[H]N([H])C([C@](CCN1CCCCC1)(CCN(C(C)C)C(C)=O)c1ccccc1[Cl])=O	2.6	5.43		7.9	12.0	 Cook, Chyung S.; Ames, Gregory B.; Smith, Margaret E.; Kowalski, Kenneth G.; Karim, Aziz. Absorption and disposition of a new antiarrhythmic agent bidisomide in man. Pharmaceutical Research, 1993, 10 (11), 1675-1682. 	Data from 1 mg/kg 20 min iv infusion, N=6, 70 kg average weight. t½ taken as the γ phase		1986	407.98	5	1	66.6	9	cationic	2.9	1.8	train
YM155	781661-94-7	c1(n(c2c(C(=O)c3ccccc3C2=O)[n+]1Cc1cnccn1)CCOC)C	23.7	11.3		34.5	24.8	Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. Anthony W. Tolcher, Alain Mita, Lionel D. Lewis, Christopher R. Garrett, Elizabeth Till, Adil I. Daud, Amita Patnaik, Kyri Papadopoulos, Chris Takimoto, Pamela Bartels, Anne Keating, and Scott Antonia. J. Cin. Onc. 2008, 26, 5198-5203.	Sepantronium bromide. 3.6 (N=7) and 4.8 mg/m2 (N=25). Weighted average from data reported on Table 4. T1/2 questionable. 168 hr infusion. Quaternary ammonium salt. Bromide counter-ion omitted from smiles.		2001	363.39	7	0	78.0	5	neutral	-1.2	-1.2	train
(+)dOTC	160707-68-6	c1cn(c(=O)nc1N)[C@@H]2CO[C@@H](S2)CO	0.84	3.9		3.6	8.92	PATRICK F. SMITH, ALAN FORREST, CHARLES H. BALLOW, DAVID E. MARTIN,AND LOUISE PROULX. Absolute Bioavailability and Disposition of (-) and (+) 2'-Deoxy-3'-Oxa-4'-Thiocytidine (dOTC) following Single Intravenousand Oral Doses of Racemic dOTC in Humans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2000, 44,1609–1615.	Dosed as 100 mg of racemate. (-) form called apricitabine or (-) BCH10652. The (+) form is called (+)-BCH 10652; (+)-DOTC; BCH 10619. Data for (-) form reported as well. MRT from VDss and clearance. 		1994	229.26	6	2	90.4	2	neutral	-1.9	-1.9	train
NBI-1	1190929-42-0	C[C@H](c1c2ccccc2sc1CCN(C)C)c1ccccn1	1.83	5.31		6.8	9.1	Ajay Madan, Zhihong O’Brien, Jianyun Wen, Chris O’Brien, Robert H. Farber, Graham Beaton, Paul Crowe, Berend Oosterhuis, R. Colin Garner, Graham Lappin,  Haig P. Bozigian.  A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009, 67, 288–298	microdosing, 100 ug. N=4, median values reported. 70kg average weight assumed. However, diphenhydramine reported values differed significantly from data in non microdosing study. See above.		2009	310.46	2	0	16.1	5	cationic	3.8	1.9	train
Nafcillin	147-52-4	CCOc1ccc2ccccc2c1C(=O)N[C@H]3[C@H]4SC(C)(C)[C@@H](N4C3=O)C(=O)O	0.22	3.3	0.13	1.1	0.7	Waller ES, Sharanevych MA, and Yakatan GJ (1982) The effect of probenecid on nafcillin disposition.  J. Clin. Pharmacol.  22: 482-489.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.	VDss calculated using micro rate constants reported in the reference.  Note: Plasma concentrations determined by bioassay; assumes no active metabolites.		1962	414.47	7	2	95.9	5	anionic	3.5	0.18	train
Perindoprilat	95153-31-4	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O)C(=O)O	0.76	1.7	0.16	7.6	29.0	Devissaguet JP, Ammoury N, Devissaguet M, and Perret L (1990) Pharmacokinetics of perindopril and its metabolites in healthy volunteers.  Fundam. Clin. Pharmacol. 4: 175-189.  Parker E, Aarons L, Rowland M, and Resplandy G (2005) The pharmacokinetics of perindoprilat in normal volunteers and patients: Influence of age and disease state.  Eur. J. Pharm. Sci. 26: 104-113.	VDss calculated from data obtained by digitization of a plot in the reference. 		1984	340.41	7	3	106.9	7	anionic	0.92	-3.2	train
Topotecan	123948-87-8	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(Cc4cc5c(CN(C)C)c(O)ccc5nc34)C2=O	1.8	13.0	0.65	2.3	2.3	Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, and Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.  Br. J. Canc. 73: 1268-1271.  van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, de Boer-Dennert M, Maes RAA, and Beijnen JH (1995) Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.  Canc. Chemother. Pharmacol. 35: 237-245.  Masubuchi N, May RD, and Atsumi R (2004) A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage Assay.  Clin. Cancer Res. 10: 6722-6731.			1957	421.45	8	2	103.2	3	cationic	1.3	-1.5	train
Cefepime	88040-23-7	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)[O-])C[N+]3(C)CCCC3)\c4csc(N)n4	0.28	2.2	0.78	2.1	1.9	Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.  Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, and Martin RR (1992) Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother. 36: 552-557			1983	480.56	11	2	150.0	7	anionic	-3.6	-2.7	train
Ergotamine	113-15-5	CN1C[C@@H](C=C2[C@H]1Cc3c[nH]c4cccc2c34)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](Cc8ccccc8)N6C5=O	3.6	15.0	0.02	4.0	2.1	Ibraheem JJ, Paalzow L, and Tfelt-Hansen P (1985) Linear pharmacokinetics of intravenous ergotamine tartrate.  Eur. J. Clin. Pharmacol. 29: 61-66.	VDss calculated from compartmental parameters provided in the reference.		1920	581.66	10	3	118.2	4	neutral	3.6	3.5	train
Tesaglitazar	251565-85-2	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(=O)(=O)C)cc2)cc1)C(=O)O	0.13	0.039	0.0011	56.0	45.0	Ericsson H, Hamren B, Bergstrand S, Elebring M, Fryklund L, Heijer M, and Ohman KP (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dual acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.  Drug Metab. Dispos.  32: 923-929.			1999	408.47	7	1	99.1	11	anionic	2.7	-0.53	train
Nomifensine	24526-64-5	CN1CC(c2ccccc2)c3cccc(N)c3C1	6.0	22.0	0.4	4.5	6.5	Lindberg RLP, Syvalahti EKG, and Pihlajamaki KK (1986) Disposition of nomifensine after acute and prolonged dosing.  Clin. Pharmacol. Ther. 39: 384-388.  Heptner W, Hornke I, Cavagna F, Fehlhaber HW, Rupp W, and Neubauer HP (1978) Metabolism of nomifensine in man and animal species.  Arz. Forsch. 28: 58-64	VDss calculated from data obtained by digitization of a plot in the reference. 		1969	238.33	2	1	29.3	1	cationic	2.3	0.87	train
Trimipramine	739-71-9	CC(CN(C)C)CN1c2ccccc2CCc3ccccc13	16.0	16.0	0.0509999999999999	17.0	23.0	Abernethy DR, Greenblatt DJ, and Shader RI (1984) Trimipramine kinetics and absolute bioavailability:  use of gas-liquid chromatography with nitrogen-phosphorus detection.  Clin. Pharmacol. Ther. 35: 348-353.	VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.		1952	294.43	2	0	6.5	4	cationic	4.6	3.1	train
Rosaramicin	35834-26-5	C1=CC([C@@H](C[C@@H]([C@@H]([C@@H](C)[C@@H](CC(O[C@@H]([C@@H](C)[C@@H]2O[C@@]12C)CC)=O)O)O[C@@H]1O[C@@H](C[C@@H]([C@@H]1O)N(C)C)C)CC=O)C)=O	2.83	13.3		3.54	3.34	Pharmacokinetics and Metabolism of Rosaramicin in Humans. CHIN-CHUNG LIN, MENGER CHUNG, RICHARD GURAL, DAVID SCHUESSLER, HONG-KI KIM, ELAINERADWANSKI, ALICEANN MARCO, CHARLES DiGIORE, AND SAMSON SYMCHOWICZ. Antimicr. Agents Chemother. 1984, 26, 522-526.	Data digitized from plot reported by Lin et al . N=12 74.4 kg average weight estimated from dose/AUC vs. clearance in mL.min-1.kg-1 reported. 500 mg dose administered as 1-hr infusion. Reported clearance 13.4 mL.min-1.kg-1 and 3.78 L/kg as Vdarea. Calculated VDz 3.86 L/kg. AUC calculated 8.38 hr*ug/mL vs. reported as 8.35 hr*ug/mL.		1971	581.74	10	2	135.1	6	cationic	2.5	1.2	train
Gestodene	60282-87-3	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	0.46	0.8	0.023	9.6	10.0	Tauber U, Tack JW, and Matthes H (1989) Single dose phakmacokinetics of gestodene in women after intravenous and oral administration.  Contraception 40: 461-476.    Kuhnz W, Pfeffer M,and Al-Yacoub G (1990) Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.  J. Steroid Biochem. 35: 313-318.  Gui LQ and Humpel M (1990) Serum protein binding characteristics of cyproterene acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man.  J. Steroid Biochem. 35: 319-326.	VDss deteremined from Cvs t data obtained by digitization of plots in Tauber, 1989.  Protein binding very different in two reports: 0.006 in Kuhnz et al vs 0.04 in Gui and Humpel; value entered is the average.		1977	310.43	2	1	37.3	2	neutral	4.1	4.1	train
Indacaterol	312753-06-3	[C@@H](O)(c1ccc(c2c1ccc(=O)[nH]2)O)CNC1Cc2c(C1)cc(c(c2)CC)CC	19.4	4.48	0.05	72.4	92.5	Pharmapendium. Indacaterol Maleate - FDA Approval PackageClinical Pharmacology and Biopharmaceutics Review 022383/S-000 Part 02. Data from Table 1 on page 4 of 47.	200 ug iv dose. 70 kg assumed. MRT from VDss and Cl. Plasma protein binding from PDR. Accessed February 22 2013.		2000	392.49	5	4	85.3	6	cationic	2.6	0.27	train
Nedocromil	69049-73-6	c12c(c3c(c(cc(o3)C(O)=O)=O)cc1c(cc(n2CC)C(O)=O)=O)CCC	0.43	10.2	0.11	0.7	0.9	M. G. NEALE, K. BROWN, R. A. FOULDS, S. LAL1, D. A. MORRIS & D. THOMAS. The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. Br. J. Clin. Pharmacol.  (1987), 24, 493-501//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf. Accessed June 15 2017.	420 ug total dose administered as 0.2 ug.kg-1.min-1 in 30 minutes. 70 kg average weight N=6 healthy. MRT from VDss and clearance.	80% excreted unchanged also reported in the FDA approval package. Very small amount excreted in urine after po or inhalation.	1978	371.34	8	2	127.1	5	anionic	2.8	-3.1	train
Bunazosin	80755-51-7	CCCC(=O)N1CCCN(CC1)c2nc(N)c3cc(OC)c(OC)cc3n2	0.72	4.8	0.06	2.5	2.0	Morishita N, Tomono Y, Hasegawa J, and Heuer HJ (1993)  Single dose crossover study to evaluate the absolute bioavailability of a sustained-release formulation of bunazosin (E1015) in healthy male volunteers.  Drug Invest.  6:  5-9.  Yamato C, Takahashi T, Tadano K, Kinoshita K, and Fujita T (1985)  The metabolic fate of bunazosin hydrochloride (2). Studies on the transfer to fetus and milk, plasma protein binding, tissue accumulation and effect on drug-metabolizing enzymes. Oyo Yakuri  30: 257-265.			1980	373.45	8	1	93.8	5	neutral	2.7	2.6	test
Fosfluconazole	194798-83-9	OP(=O)(O)OC(Cn1cncn1)(Cn2cncn2)c3ccc(F)cc3F	0.15	1.3	0.042	2.0	2.1	Sobue S, Tan K,  Layton G, Leclerc V, and Weil A (2004) The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.  Br. J. Clin. Pharmacol. 57: 773-784.			1997	386.25	10	2	128.2	7	anionic	-0.79	-5.1	train
Danusertib	827318-97-8	N(C(=O)C(=CC=C1N(CCN2C)CC2)C=C1)C(C(=C1C2)CN2C([C@H](OC)C(=CC=C2)C=C2)=O)=NN1	2.5	6.1		6.8	25.0	Weighted data digitized from Fig. 1B (N=12, dose 500 mg/m2 (12.5 mg/kg) 24h i.v. infusion) and Fig. 1C (N=6, dose 750 mg/m2 (18.75 mg/kg) 24h i.v. infusion) in Cohen, Roger B.; Jones, Suzanne F.; Aggarwal, Charu; von Mehren, Margaret; Cheng, Jonathan; Spigel, David R.; Greco, F. Anthony; Mariani, Mariangela; Rocchetti, Maurizio; Ceruti, Roberta; Comis, Silvia; Laffranchi, Bernard; Moll, Jurgen; Burris, Howard A.  A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors.   Clinical Cancer Research  (2009),  15(21),  6694-6701.	The Fig. 4 is not plotted in van Tellingen O. et al, Cancer Chemother Pharmacol, 1998, 41, 377-384 where another patient profile with a different dose is shown in the Fig. 5		2005	474.55	9	2	93.8	6	cationic	1.6	0.62	train
Sparfloxacin	110871-86-8	C[C@@H]1CN(C[C@H](C)N1)c2c(F)c(N)c3C(=O)C(=CN(C4CC4)c3c2F)C(=O)O	3.9	2.7	0.55	24.0	20.0	Zagam Product Label. Montay. G. Journal of Antimicrobial Chemotherapy (1996), 37, Suppl. A, 27-39 Pharmacokinetics of sparfloxacin in healthy volunteers and patients			1987	392.4	7	3	98.9	3	zwitterionic	2.7	-0.36	train
Lesinurad	878672-00-5	c1ccc2c(c1)c(ccc2n3c(nnc3Br)SCC(=O)O)C4CC4	0.29	1.43	0.02	3.33	5.0	http://irwdpi.com/zurampic/zurampic.pdf#page=1 Prescribing information. Accessed February 27, 2017.	RDEA594, Zurampic. Absolute BA approximately 100%. 70 kg average weioght assumed. MRT from clearance and VDss. Ppb reported as > 98%.		2006	404.28	5	1	68.0	5	anionic	2.4	-0.86	test
Bepridil	64706-54-3	N(c1ccccc1)(C[C@@H](N1CCCC1)COCC(C)C)Cc1ccccc1	10.1	8.7	0.001	19.3	14.9	Pharmacokinetics of intravenous bepridil in patients with coronary disease By Lesko, Lawrence J.; Benotti, Joseph R.; Alpert, Joseph S.; Brady, Priscilla M.; McCue, Jane E.; Weiner, Bonnie H.; Ockene, Ira S. From Journal of Pharmaceutical Sciences (1986), 75(10), 952-4. ppb: NIGEL J. WATERS, RACHEL JONES, GARETH WILLIAMS, BINDI SOHAL (2008). Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding, 97, 4586-4595.	MRT= VDss/CL. N=10. All patients with normal baseline hemodynamic and renal functions. Plots available.		1977	366.54	3	0	15.7	10	cationic	5.4	4.9	train
Ritipenem 	84845-58-9	C1(=O)N2[C@@H]([C@H]1[C@H](O)C)SC(COC(N)=O)=C2C(=O)[O-].[Na+]	0.24	7.55	0.72	0.54	0.54	. Weighted data for diverse doses and number of patients (N=61) from Table XII (BW 65-80 kg) in Lovering, A. M.; White, L. O.; Lewis, D. A.; MacGowan, A. P.; Routh, K. R.; Pickin, D. M.; Reeves, D. S.  Pharmacokinetics of FCE 22101 in man following different modes of administration.    Journal of Antimicrobial Chemotherapy  (1989),  23(Suppl. C),  179-95; and from Table 2 in Jannuzzo, M. G.; Mandelli, M.; Strolin Benedetti, M.; Moro, E.; Carnovali, M.; Vaiani, R.; Sassella, D.  Pharmacokinetics and tolerance of a new penem antibiotic, FCF 22101, in healthy volunteers after a single intravenous dose.    European Journal of Clinical Pharmacology  (1989),  36(6),  633-635.    fu in Efthymiopoulos, C.; Battaglia, R.; Strolin Benedetti, M.  Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic.    Journal of Antimicrobial Chemotherapy  (1991),  27(4),  517-26.	FCE-22101. In Jannuzzo et al the renal CL = 1.94 mL/min/kg was also reported. CAS number reported refers to sodium salt. Parent compound CAS 84845-57-8.		1982	310.26	8	2	133.0	5	anionic	-2.1	-5.6	train
Tofogliflozin	903565-83-3	CCc1ccc(cc1)Cc2ccc3c(c2)[C@]4([C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC3	0.63	2.07	0.46	5.1	4.7	Dietmar Schwab, Agnes Portron, Zoe Backholer, Berthold Lausecker, Kosuke Kawashima.  A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans. Clin Pharmacokinet 2013, 52, 463–473.	Microdose, 100 ug total, N=6, 80.4 kg average reported weight.		2006	386.44	6	4	99.4	4	neutral	1.6	1.6	train
Tobramycin	32986-56-4	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	0.23	1.6	1.0	2.4	2.0	Bourget P, Fernandez H, Delouis C, abd Taburet AM (1991) Pharmacokinetics of tobramycin in pregnant women, safety and efficacy of a once-daily dose regimen.  J. Clin. Pharm. Ther.  16: 167-176.  Champoux N, Du Souich P, Ravaoarinoro M, Phaneuf D, Latour J, and Cusson JR (1996) Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers.  Br. J. Clin. Pharmacol. 42: 325-331.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.	Data from Champeaux et al was digitized to calculate parameters.  		1971	467.51	14	10	268.2	6	cationic	-7.0	-8.5	train
Bilobalide	33570-04-6	CC(C)(C)C1(O)CC2OC(=O)CC23C(=O)OC4OC(=O)C(O)C134	2.5	10.0		4.0	3.2	Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biolba (EGb 761).  Therapie  50: 137-144.			1971	326.3	8	2	119.4	0	neutral	-3.4	-3.4	train
Valdecoxib	181695-72-7	o1nc(c(c1C)c1ccc(cc1)S(=O)(=O)N)c1ccccc1	0.75	1.4	0.02	9.4	7.4	Valdecoxib - FDA Approval PackageClinical Pharmacology and Biopharmaceutics Review 021341/S-000 Part 02	72.5 median weight reported. 10 mg administered as 30' infusion. N=24. 	Valdecoxib - FDA Approval PackageClinical Pharmacology and Biopharmaceutics Review 021341/S-000 Part 02	1996	314.36	5	1	86.5	3	neutral	2.5	2.5	train
Abacavir	136470-78-5	Nc1nc(NC2CC2)c3ncn([C@@H]4C[C@H](CO)C=C4)c3n1	0.84	13.0	0.5	1.1	1.0	Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, and Stein DS. (1999) Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food.    Pharmacotherapy 19: 932-942.  Ziagen Product Label.			1991	286.33	7	3	101.9	4	neutral	0.99	0.99	test
Dalfampridine	504-24-5	c1(ccncc1)N	2.6	9.3	1.0	4.7	3.6	Donald R. A. Uges, Pharm.D., Yung Jai Sohn, M.D.,* Ben Greijdanus,Arnold H. J. Scat, Ph.D., Sandor Agoston, M.D., Ph.D. 4-Aminopyridine kinetics. Clin. Pharmacol. Ther. 1982, 31, 587-593.	4-aminopyridine. N=9 (7M and 2F). 71.6 kg average weight, 20 mg dose.	Donald R. A. Uges, Pharm.D., Yung Jai Sohn, M.D.,* Ben Greijdanus,Arnold H. J. Scat, Ph.D., Sandor Agoston, M.D., Ph.D. 4-Aminopyridine kinetics. Clin. Pharmacol. Ther. 1982, 31, 587-593. Approximately 90% excreted unchanged in urine.	1915	94.11	2	1	38.9	0	cationic	-0.12	-1.4	train
Iopentol	89797-00-2	c1(c(c(c(I)c(c1I)C(NC[C@@H](CO)O)=O)C(NC[C@@H](CO)O)=O)I)N(C[C@@H](COC)O)C(C)=O	0.2	1.27	1.0	2.64	2.04	Waaler A; Jorgensen N P; Koksvik B; Skinnemoen K; Andrew E. Pharmacokinetics of iopentol in healthy volunteers. Acta radiol. Suppl. 1987, 370, 113-117.//ppb: Thomas Lehnert, Erich Keller, Klaus Gondolf, Tanja Schäffner, Hermann Pavenstädt and Peter Schollmeyer. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant, 1998, 13,358–362.	Dose expressed in gI/kg. 2.19 correction factor for MW of iopentol (reported as such in plot). Dose digitized 1.2 gI/kg corresponding to 2.36 gI/kg of iopentol. Digitization yielded clearance within 20% of reported. No AUC available. Linear kinetics within range of doses. N =8, 74 kg average weight, infusion time 5.5 min	Completely excreted renally. Unchanged	1984	835.16	12	7	188.9	13	neutral	-2.2	-2.2	train
Tacrine	321-64-2	Nc1c2CCCCc2nc3ccccc13	11.0	56.0	0.25	3.3	3.3	Lou G, Montgomery PR, and Sitar DS (1996) Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.  J. Psych. Neurosci.  21: 334-339.  Makela PM, Truman CA, Ford JM, and Roberts CJC (1994) Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease. Eur. J. Clin. Pharmacol. 47:  151-155.			1945	198.26	2	1	38.9	0	cationic	3.3	0.83	train
PR-104	851627-62-8	N(CCO[S](C)(=O)=O)(CC[Br])C(=C(C(NCCO[P](=O)(O)O)=O)C=C1N(=O)=O)C(N(=O)=O)=C1	0.86	44.8		0.32	0.1	A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients Mark J McKeage, Yongchuan Gu, William R Wilson, Andrew Hill, Karen Amies, Teresa J Melink and Michael B Jameson. BMC Cancer 2011, 11:432.	Phosphate pre-prodrug. Weighted average across 135-900  mg/m2 doses. N= 25 total patients. 1hr intravenous infusion of day 1 of cycle 1. MRT calculated from VDss and clearance averages.		2005	579.27	16	3	234.1	14	anionic	0.27	-4.6	train
Elinafide	162706-37-8	C(CCNCCN1C(=O)c2c(ccc3ccccc23)C1=O)NCCN1C(=O)c2c(ccc3ccccc23)C1=O	12.0	5.7		35.2	52.6	Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies Miguel A. Villalona-Calero, Joseph P. Eder, Deborah L. Toppmeyer, Lee F. Allen, Robert Fram, Raja Velagapudi, Michael Myers, Anthony Amato, Kathleen Kagen-Hallet, Betty Razvillas, Donald W. Kufe, Daniel D. Von Hoff, and Eric K. Rowinsky. Journal of Clinical Oncology, 2001 19, 857-869.	LU79553. N=14 across doses ranging from 2 to 24 mg/m2/day.		1995	520.58	8	2	98.8	10	cationic	3.7	2.9	test
Spectinomycin	1695-77-8	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	0.13	0.99		2.2	1.8	Wagner, JG, Novak, E, Leslie, LG, Metzler, CM (1968) Absorption, distribution and elimination of spectinomycin dihydrochloride in man.  Int. Zeit. Klin. Pharmakol. Ther. Toxikol. 1: 261-285. 	VDss calculated from C vs t data obtained by digitization of plots in the reference.		1961	332.35	9	5	129.5	2	cationic	-2.9	-5.3	train
Peldesine	133432-71-0	c12c(Cc3cccnc3)c[nH]c1c([nH]c(n2)N)=O	1.2	6.2	0.86	3.2	3.0	Viegas TX, Omura GA, Stoltz RR, Kisicki J.Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2000 Apr;40(4):410-20.	BCX-34. data digitized from figure 3. N=9, 18 mg/m2 (1.9 m2 average BSA, 77 kg average weight) in 30' infusion.reported AUC= 1104 hr*ng/mLreported clearance = 33.3 L/hreported t1/2 = 2.1 h	Calculated from the ratio of Ae (29 mg) and dose (18 mg/m2*1.9m2 = 34.2 mg)	1991	241.25	6	3	100.5	2	neutral	-0.38	-0.38	train
Carebastine	90729-42-3	C1C(CCN(C1)CCCC(c1ccc(C(C(=O)O)(C)C)cc1)=O)OC(c1ccccc1)c1ccccc1	0.41	0.4	0.05	16.7	9.8	J.M. JANSAT, C.F. LASTRA, E.L. MARINO Comparative study of different weighting methods in non-linear regression analysis: implications in the parametrization of carebastine after intravenous administration in healthy volunteers. Int. J. Clin. Pharmacol. Ther., Vol. 1998, 36, 340-344.//ppb: A del Cuvillo, J Mullol, J Bartra, I Dávila, I Jáuregui, J Montoro, J Sastre, AL Valero. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006, 16, Suppl. 1:3-12.	Data taken from Table 1. 77 kg median weight, 10 mg total dose. N=8. VDss from MRT and clearance.		1985	499.64	5	1	66.8	11	zwitterionic	5.9	3.0	test
Maraviroc	376348-65-1	[H]N(C(C1CCC(CC1)(F)F)=O)[C@H](CCN1[C@H]2CC[C@@H]1CC(C2)n1c(C)nnc1C(C)C)c1ccccc1	2.3	9.4	0.25	4.2	12.8	Abel S. et al. (2008) Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy males subjects. Br. J. Clin. Pharmacol. 65:Suppl.1 60-67//ppb from Walker et al. DMD 2005, 33, 587-595	N=8 in study 2 cohort 1 and N=8 in cohort 2. Overall average weight 80 kg, average of two cohhorts at 30 mg i.v.		2001	513.67	6	1	63.0	8	cationic	4.5	3.1	train
Tetrahydrocannabinol, D9-	1972-08-3	CCCCCc1cc(O)c2[C@@H]3C=C(C)CC[C@H]3C(C)(C)Oc2c1	8.9	3.2	0.05	46.0	33.0	Wall ME, Sadler BM, Brine D, Taylor H, and Perez-Reyes M (1983)  Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.  Clin. Pharmacol. Ther. 34: 352-363.  Busto U, Bendayan R, and Sellers EM (1989) Clinical pharmacokinetics of non-opiate abused drugs.  Clin. Pharmacokinet. 16: 1-26.	Dronabinol. Δ9-THC. VDss was calculated using C vs t data  provided in the reference.		1940	314.46	2	1	29.5	4	neutral	7.0	7.0	test
Nisoldipine	63675-72-9	COC(=O)C1=C(C)NC(=C(C1c2ccccc2N(=O)=O)C(=O)OCC(C)C)C	5.5	15.0	0.003	6.5	11.0	van Harten J, van Brummelen P, Lodewijks MTM, Danhof M, Breimer DD (1988) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.  Clin. Pharmacol. Ther. 43: 332-341.  van Harten J, van Brummelen P, Wilson JHP, Lodewijks MTM, and Breimer DD (1988) Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 387-394.  			1977	388.41	8	1	110.4	8	neutral	3.7	3.7	train
Propranolol	525-66-6	CC(C)NCC(O)COc1cccc2ccccc12	3.1	12.0	0.13	4.3	3.4	Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.  Br. J. Clin. Pharmacol. 11: 119P-120P.  Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers.  Br. J. Clin. Pharmacol. 43: 563-570. 			1964	259.34	3	2	41.5	6	cationic	2.7	0.93	train
Tolterodine	124937-51-5	CC(C)N(CC[C@H](c1ccccc1)c2cc(C)ccc2O)C(C)C	1.5	8.4	0.0369999999999999	3.0	2.4	Brynne N, Stahl MMS, Hallen B, Edlund PO, Palmer L, Hoglund P, and Gabrielsson J (1997) Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.  Int. J. Clin. Pharmacol. Ther. 35: 287-295.  Brynne N, Dalen P, Alvan G, Bertilsson L, and Gabrielsson J (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine.  Clin. Pharmacol. Ther. 63: 529-539.  Pahlman I and Gozzi P (1999) Serum protein binding of tolterodine and its major metabolites in humans and several animal species.  Biopharm. Drug Dispos. 20: 91-99.	Data from CYP2D6 EM subjects included.		1989	325.49	2	1	23.5	7	cationic	5.4	3.6	train
Fleroxacin	79660-72-3	CN1CCN(CC1)c2c(F)cc3C(=O)C(=CN(CCF)c3c2F)C(=O)O	1.6	2.4	0.73	11.0	8.6	Weidekamm E, Portmann R, Suter K, Partos C, Dell D, and Lucker PW (1987) Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.  Antimic. Agents Chemother. 31: 1909-1914.  Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750.			1981	369.34	6	1	64.1	4	zwitterionic	2.0	-0.27	test
Bosentan	147536-97-8	COc1ccccc1Oc2c(NS(=O)(=O)c3ccc(cc3)C(C)(C)C)nc(nc2OCCO)c4ncccn4	0.29	2.1	0.0369999999999999	2.3	4.1	Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, Van Marle S, Viischer HW, and Jonkman JHG (1999)  Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.  J. Clin. Pharmacol. 39:  703-714.  Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Van Marle SP, Peeters PAM, Jonkman JHG, and Jones CR (1996) Pharmacokinetics pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.  Clin. Pharmacol. Ther. 60: 124-137.			1992	551.61	11	2	145.6	10	anionic	3.9	0.76	train
Dezocine	53648-55-8	c12[C@@]3([C@H]([C@@H](CCCCC3)Cc1ccc(c2)O)N)C	5.6	27.5	0.08	4.6	3.9	Wilson JM, Cohen RI, Kezer EA, Schange SJ, Smith ER. Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain.J Clin Pharmacol. 1995 Apr;35(4):398-403.	Doses from 5-20. averaged by authors.		1976	245.36	2	2	46.3	0	cationic	3.0	1.1	train
Sipatrigine	130800-90-7	c1(c2c(nc(N3CCN(C)CC3)nc2)N)c(c(cc(c1)Cl)Cl)Cl	15.31	20.9		12.26	10.98	A. J. MERCER, R. J. LAMB, HUSSEIN, S. HOBBIGER, J. POSNER. The Tolerability, Pharmacokinetics and Pharmacodynamics of Increasing Intravenous Doses of 619C89, a Novel Compound for the Acute Treatment of Stroke, in Healthy Volunteers. Ann N. Y. Acad. Sci., 1995, 754, 324-326.	 619C89. Data digitized from reported plot. 1 mg/kg only but linear PK. N=8, 70 kg average weight assumed. Reported AUCinf = 885 ng.hr.mL-1. Calculated 798 ng.hr.mL-1 (11% difference). Clearance reported 1.2 L.hr-1.kg-1. Calculated 1.25 L.hr-1.kg-1.	in STROKE PATIENTS: Z. HUSSEIN, I. J. FRASER, K. R. LEES, K. W. MUIR, M. W. LUNNON, S. F. HOBBIGER, J. POSNER. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. Br J Clin Pharmacol 1996; 41: 505–511//619C89. 5 dose groups (loading and maintenance infusion). Data were weight averaged accoding to number of patients. N=23 overall (N=22 for t1/2). Reported mean body weight 74 kg.	1990	372.68	5	1	58.3	2	cationic	4.4	3.6	train
Conivaptan	210101-16-9	Cc1nc2CCN(C(=O)c3ccc(NC(=O)c4ccccc4c5ccccc5)cc3)c6ccccc6c2[nH]1	0.76	3.0	0.01	4.2	6.7	Vaprisol Product Label	VDss was calculated using C vs t data obtained by digitization of the plot provided in the product label.		1998	498.57	6	2	78.1	4	cationic	5.5	5.0	test
Telithromycin	191114-48-4	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCn4cnc(c4)c5cccnc5)C(=O)O[C@]13C)OC	3.0	14.0	0.41	3.6	12.0	Perret C, Lenfant B, Weinling E, Wessels DH, Scholtz HE, Montay G, and Sultan E (2002) Pharmacokinetics and Absolute Oral Bioavailability of an 800-mg Oral Dose of Telithromycin in Healthy Young and Elderly Volunteers.  Chemotherapy 48: 217-223.  Yamazaki H, Lamy S, Ducelier C, Bonnat C, and Lenfant B (2003) Study of binding of telithromycin to human serum proteins. Nippon Kagaku Ryoho Gakkai Zasshi  51: 206-209. 			1995	812.0	15	1	171.8	11	cationic	3.7	2.4	test
Laromustine	173424-77-6	CS(=O)(=O)[N@@](N(S(=O)(=O)C)C(=O)NC)CCCl	0.88	23.1		0.63	0.49	A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory LeukemiaFrancis Giles, Deborah Thomas,Guillermo Garcia-Manero, Stefan Faderl,Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli,Sima Jeha,Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill,Caroline Clairmont, Mario Sznol, and Hagop Kantarjian Cli. Cancer Res. 2004 Vol. 10, 2908–2917.	VNP40101M or cloretazine. Dose range from 220 to 708 ,g/m2. Weighted average across number of courses for each dose. MRT calculated from VDss and clearance reported. Variable infusion time (15-70 minutes)		1996	307.78	8	1	103.9	5	neutral	-1.4	-1.4	train
Methyldopa	555-30-6	C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O	0.69	3.5	0.85	3.3	5.9	Skerjanec A, Campbell NRC, Robertson S, and Tam YK (1995) Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects.  J. Clin. Pharmacol. 35: 275-280.  Stenbaek O, Myhre E, Rugstag HE, Arnold E, and Hansen T (1977) Pharmacokinetics of methyldopa in healthy man.  Eur. J. Clin. Pharmacol. 12: 117-123.  Myhre E, Rugstad HE, and Hansen T (1982) Clinical pharmacokinetics of methyldopa.  Clin. Pharmacokinet. 7: 221-233.			1952	211.21	5	4	103.8	3	zwitterionic	0.66	-2.1	test
Homoharringtonine	26833-87-4	[C@@]123[C@@H]([C@@H](C(=C1)OC)OC(=O)[C@](CC(=O)OC)(O)CCCC(O)(C)C)c1c(cc4c(c1)OCO4)CCN2CCC3	1.8	2.96		10.2	9.8	Clinical pharmacology of homoharringtonine Savaraj N; Lu K; Dimery I; Feun L G; Burgess M; Keating M; Loo T L Cancer treatment reports (1986), 70(12), 1403-7.  	Omacetaxine mepesuccinate Reported averages in table 1 for HHT. Dosed by 6-hour infusion at 3-4 mg/m2, N=8. MRT from Cl and VDss.		1970	545.62	10	2	124.0	10	cationic	0.95	0.17	train
Dicloxacillin	3116-76-5	Cc1onc(c1C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4c(Cl)cccc4Cl	0.11	2.0	0.033	0.92	0.88	Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 9, 42-48.  Roder BL, Frimodt-Moller, Espersen F, and Rasumussen SN (1995) Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bacteriocidal titers in healthy subjects after oral administration.  Infection 23: 107-112.	VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  		1964	470.33	8	2	113.0	4	anionic	3.3	0.023	train
Endralazine	39715-02-1	N\N=C\1/NN=C2CCN(CC2=C1)C(=O)c3ccccc3	2.2	13.0		2.7	5.6	Reece PA, Cozamanis I, and Zacest R (1983) Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability.  Eur. J. Clin. Pharmacol. 25: 553-556.			1972	269.3	6	2	83.1	1	cationic	1.9	1.9	test
Dobesilic acid	88-46-0	O=S(=O)(O)c1c(O)ccc(O)c1	0.12	0.87		2.41	2.01	G. Franke, T. Schneider, W. Siegmund, A. Scherber. Bioavailability studies of calcium dobesilate- a case of flip-flop kinetics. Pharmazie, 1985, 40, 562-563. 	N=10, iv bolus, 500 mg dose, 68.7 kg average weight. AUCinf digitized 139.7 mg.h.L-1, reported 139 mg.hr.L-1 (AUC0-t digitized 137.4 mg.hr.L-1). 	Administered as calcium salt. Structure and CAS# refers to neutral compound.	1923	190.17	5	3	94.8	1	neutral	-1.1	-4.0	train
Repinotan	144980-29-0	O=C1N(CCCCNC[C@H]2CCc3ccccc3O2)S(=O)(=O)c4ccccc14	0.21	2.2		1.6	1.2	Heining R,  Sundaresan P, Shah A and Boettcher M (2005) Effect of Gender and Age on the Pharmacokinetics of Repinotan.  Clin. Drug. Invest. 25: 125-134.  			1992	400.49	6	1	75.7	7	cationic	3.9	3.5	train
CEP-18770	847499-27-8	C(N[C@H](C(N[C@@H](CC(C)C)[B](O)O)=O)[C@@H](C)O)(=O)C(=NC(=C1)C(=C2)C=CC=C2)C=C1	0.87	0.29		50.6	42.1	Sala F et al. Development and validation of a high-performance liquid chromatography–tandemmass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study. J. Mass. Spectrom. 2010, 45, 1299–1305	Data digitized from figure 4	Delanzomib. Data received by Dr. M. Zucchetti, Mario Negri Research Institute, Milan, Italy.  See also Gallerani, Zucchetti et al. Eur. J.  Cancer 2013, 49, 290-296.	2005	413.28	8	5	131.8	9	neutral	1.9	1.9	train
Bumecaine	30103-44-7	CCCCN1CCCC1C(=O)Nc2c(cc(cc2C)C)C	1.73	19.19		1.51	1.58	Piotrovskii, V. K.; Blagodatskikh, S. V.; Ryabokon, O. S.; Metelitsa, V. I.; Smirnov, V. K.; Gorshkov, V. A.; Mazur, N. A.; Pryanishnikova, N. T.  Clinical pharmacokinetics of pyromecaine. I. Single intravenous administration Khimiko-Farmatsevticheskii Zhurnal (1983), 17(12), 1427-32	Pyromecaine. N=10 all male patients, 100 mg iv dose. MRT from reported clearance and VDss.		1970	288.43	3	1	32.3	5	cationic	4.0	3.3	train
Carboplatin	41575-94-4	N[Pt+2]1(N)[O-]C(=O)C2(CCC2)C(=O)[O-]1	0.26	1.5	1.0	3.0	2.0	Elferink F, van der Vijgh WJ, Klein I, Vermorken JB, Gall HE, and Pinedo HM (1987) Pharmacokinetics of carboplatin after i.v. administration.    Cancer Treatment Rep.  71: 1231-1237.  Gaver RC, George AM, and Deeb G (1987) In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.  Cancer Chemother. Pharmacol. 20: 271-276.	Used 1.6 m2 = 60 kg since the study was done in all females.		1982	369.24	6	2	108.8	0				train
Disopyramide	3737-09-5	CC(C)N(CCC(C(=O)N)(c1ccccc1)c2ccccn2)C(C)C	0.52	0.9	0.16	9.6	7.0	Lima JJ, Haughey DB, and Leier CV (1984) Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.  J. Pharmacokinet. Biopharm. 12: 289-313.			1962	339.47	4	1	59.2	8	cationic	2.2	-0.11	train
LY2090314	603288-22-8	C1(C2C3C(N(C(C=3C(N=C(N3C=CC4)C=4)=C3)=O)[H])=O)[C@@H](N(C=2)C2)[C@@H](C=C(C=1)F)CN(C2)C(=O)N(CCCC1)C1	1.2	10.3	0.02	1.9	2.7	Pharmacokinetics, metabolism, and excretion of the GSK-3 inhibitor LY2090314 in rats, dogs, and humans: A case study in rapid clearance by extensive metabolism with low circulating metabolite exposures. Maciej J. Zamek-Gliszczynski, Trent L. Abraham, Jeffrey J. Alberts, Palaniappan Kulanthaivel, Kimberley A. Jackson, Kay H. Chow, Denis J. McCann, Haitao Hu, Shelby Anderson, Nathan A. Furr, Robert J. Barbuch, and Kenneth C. Cassidy. Drug Metabolism & Disposition (2013), 41(4), 714-726	N=12 across dose range from 10 to 120 mg. 70 kg assumed as average weight. N=2 per dose group.		2003	514.55	9	1	90.3	2	neutral	3.5	3.5	train
Atomoxetine	83015-26-3	CNCC[C@@H](Oc1ccccc1C)c2ccccc2	0.85	9.3	0.02	1.5	5.2	Strattera Product Label	CYP2D6 EM data MRT is calculated as VD/CL; CL was calculated as CLpo/F (F=63%)		1982	255.35	2	1	21.3	6	cationic	3.6	1.5	train
Metaproterenol	586-06-1	CC(C)NCC(c1cc(cc(c1)O)O)O	6.03	14.07	0.9	7.14	6.41	Dengler HJ, Hengstmann JH. Metabolism and pharmacokinetics of orciprenaline in various animal species and man. Arch. Int. Pharmacodyn. 1976, 223, 71-87.//ppb: Heckner, R.M. Systematic study of protein binding of biologically active substances. Pharmather. 1979, 2, 177-186.	ORCIPRENALINE. N=5 after infusion (20-30') of 0.8 mg of the drug. 70 kg assumed as average weight. T1/2 calculated from 0.693/beta. MRT from VDss/clearance.		1961	211.26	4	4	72.7	4	cationic	0.56	-0.66	train
1-Aminocyclopropanecarboxylic Acid	22059-21-8	[H]N([H])C1(CC1)C(=O)O[H]	0.73	1.5		7.8	5.9	Cherkofsky, S.C. (1995) 1-Aminocyclopropylcarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships.  J. Pharm. Sci.  84: 1231-1235.			1922	101.1	3	2	63.3	3	zwitterionic	-0.66	-2.4	train
Enalaprilat	76420-72-9	C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2CCC[C@H]2C(=O)O	0.38	1.6	0.62	4.0	39.0	Hockings N, Ajayi AA, and Reid JL (1986) Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.  Br. J. Clin. Pharmacol. 21: 341-348.  Mujais  SK, Quintanilla A, Zahid M, Koch K, Shaw W, and Gibson T (1992) Renal handling of enalaprilat.    Am. J. Kidney Dis. 19: 121-125.			1980	348.39	7	3	106.9	8	anionic	0.73	-3.4	train
Bisoprolol	66722-44-9	CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1	2.4	3.7	0.66	11.0	10.0	Horikiri Y, Suzuki T, and Mizobe M (1998) Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans.  J. Pharm. Sci. 87: 289-294.  Leopold G, Pabst J, Ungethuem W, and Buehring KU (1986) Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist.  J. Clin. Pharmacol. 26: 616-621.  	VDss calculated from C vs t data obtained by digitization of the plot provided by Leopold et al.		1978	325.44	5	2	59.9	12	cationic	2.2	0.46	train
Cefodizime	69739-16-8	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)CSc3nc(C)c(CC(=O)O)s3)\c4csc(N)n4	0.054	0.61	0.18	1.5	4.2	Bryskier A, Procyk T, Tremblay D, Lenfant B, and Fourtillan JB (1990) The pharmacokinetics of cefodizime following intravenous and intramuscular administration of a single dose of 1.0 g.  J. Antimic. Chemother. 26(Suppl C): 59-63.  Scaglione F, Demartini G, Arcidiacono MM, Dugnani S, and Fraschini F (1997) Serum protein binding and extravascular diffusion of cefodizime and ceftriaxone. An in vivo study.  Clin. Drug Inv. 14: 211-216.	VDss calculated from C vs t data provided in the reference.		1978	584.67	13	4	197.4	10	anionic	1.3	-4.9	train
Amifloxacin	86393-37-5	c12c(c(c(C(O)=O)cn1NC)=O)cc(F)c(c2)N1CCN(C)CC1		4.56			4.66	Schentag J J et al. Pharmacokinetics of Amifloxacin After Oral and Intravenous Administration. Review of infectious diseases. 1989  11, suppl 5	Average of 4 (doses 200, 400, 600 every 12h and 400 every 8h, N=5  male for each one). Values reported as steady state. Average CL renal = 2.38 mL/min/kg (52% of total)		1983	334.35	7	2	77.8	3	cationic	2.4	0.2	train
Fingolimod	162359-55-9	c1(ccc(cc1)CCCCCCCC)CCC(CO)(N)CO	17.3	1.53	0.002	189.0	144.0	PP. Fingolimod Hydrochloride - FDA Approval PackagePharmacology Review 022527/S-000 Part 04	MRT from VDss and Cl. N=11, (5M/6F) 1 mg dose iv injection, reported average weight 69.1 kg. Reported source, study A0108. ppb reported as 99.7 to 99.9% across species. 99.8% taken	PDR. Accessed February 21 2013. http://www.pdr3d.com/detail.php?c=64159#section-13.  After oral administration, about 81% of the dose is slowly excreted in the urine as inactive metabolites. Fingolimod and fingolimod-phosphate are not excreted intact in urine but are the major components in the feces with amounts of each representing less than 2.5% of the dose. 	1994	307.47	3	3	66.5	12	cationic	3.7	2.6	train
Ethimizol	64-99-3	c1(c(ncn1CC)C(NC)=O)C(NC)=O	0.73	12.1	0.92	1.0	0.83	Trnovec T; Soltes L; Durisova M; Kallay Z; Koprda V; Piotrovskii L B  Pharmacokinetics of ethimizol in man. Die Pharmazie (1985), 40(6), 410-1	N=5, dose 1 mg infusion, average weight reported 69.2 kg. ppb linear across two orders of magnitude concentration ~ 10-7 to 10-9 M)		1961	210.23	6	2	76.0	3	neutral	-0.55	-0.55	train
Lenapenem	149951-16-6	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H](CCNC)O)C(=O)O)[C@@H](C)O	0.22	2.02		2.04	1.48	Mitsuyoshi Nakashlma, Toshihiko Uematsu, Kazuhiro Kosuge, Susumu Nakagawa, Shunsuke Hata and Minoni Sanada. Pharmacokinetics and safety of BO-2727, a new injectable 1-P-methyI carbapenem antibiotic, and its effect on the faecal microflora in healthy male volunteers. Journal of Antimicrobial Chemotherapy (1994) 33, 987-998.	N=18, averaged across 3 doses at 250, 500 and 1000 mg (N=6 each). 66 kg average weight reported. 73% urinary recovery.	reported as BO-2727 (HCl salt, CAS #  149882-71-3)	1993	399.5	8	5	122.1	8	zwitterionic	-1.2	-3.6	test
Glycyrrhizin	1405-86-3	C1([C@H]2[C@@]([C@@]3(C([C@H]4[C@@](CC[C@@](C4)(C(O)=O)C)(C)CC3)=C1)C)(CC[C@@H]1[C@@]2(CC[C@@H](C1(C)C)O[C@@H]1[C@H](O[C@@H]2O[C@@H]([C@@H](O)[C@@H]([C@H]2O)O)C(O)=O)[C@H]([C@H](O)[C@H](O1)C(O)=O)O)C)C)=O	0.06	0.13		7.83	8.83	Tekla G.J. van Rossum, MD, Arnold G. Vulto, PhD, Wim C. J. Hop, MSc, PhD, Solko W. Schalm, MD, PhD Pharmacokinetics of Intravenous Glycyrrhizin After Single and Multiple Doses in Patients with Chronic Hepatitis C Infection. CLlNICALTHERAPEUTICS, 1999,21, 2080-2090	Weighted average over 4 doses (80, 160, 200, 240) from table II (Day1). N=33 overall. 		1880	822.93	16	8	267.0	7	anionic	1.5	-7.5	test
Sufentanil	56030-54-7	CCC(=O)N(c1ccccc1)C2(COC)CCN(CCc3cccs3)CC2	9.4	15.0	0.0749999999999999	10.0	14.0	Hudson RJ, Bergstrom RG, Thomson IR, Sabourin MA, Rosenbloom M, and Strunin L (1989) Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery.  Anesthesiol. 70: 426-431.  Scholz J, Bause H, Schulz M, Klotz U, Krishna DR, Pohl S, Schulte am Esch J (1994) Pharmacokinetics and effects on intracranial pressure of sulfentanil in head trauma patients.  Br. J. Clin. Pharmacol. 38: 369-372.  Meuldermans WEG, Hurkmans RMA, and Heykants JJP (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.  Arch. Int. Pharmacodyn. Ther. 257: 4-19.			1976	386.55	4	0	32.8	8	cationic	3.9	2.9	train
Crizotinib	877399-52-5	C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4	22.15	9.75	0.09	37.9	38.9	Huiping Xu, P, Melissa O’Gorman, Tanya Boutros, Nicoletta Brega,  Constantino Kantaridis,  Weiwei Tan, Akintunde Bello. Evaluation of Crizotinib Absolute Bioavailability, the Bioequivalence ofThree Oral Formulations, and the Effect of Food on Crizotinib Pharmacokinetics in Healthy Subjects. J. Clin. Pharmacol., 2104, 55, 104–113.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202570s009lbl.pdf. Accessed, July 12 2017.	N=14, 50 mg iv dose, 80 kg average weight reported. MRT from VDss and clearance.		2006	450.34	6	2	78.0	5	cationic	4.3	2.3	test
Caderofloxacin	153808-85-6	n1(cc(c(c2cc(c(c(c12)OC(F)F)N1C[C@@H](NCC1)C)F)=O)C(=O)O)C1CC1	1.1	2.7		7.1	5.9	Pharmacokinetics of caderofloxacin hydrochloride after intravenous infusion in healthy volunteers. WANG Yuan-yuan，ZHANG Jing，ZHANG Deng-shan，ZOU Ying，LIU Guang-yu. Chinese Journal of New Drugs 2011, 20( 23) 2377-2380.	Caderofloxacin, CS-940. Data digitized from plot of mean data after an infusion (1 hr) of 0.4 g of compound to 10 male and female healthy volunteers. Data reported in Table 1 are average of separate PK calculations in Table 2.  Reported AUCinf as 45.1 ug.mL.h-1.  		1990	411.38	7	2	83.8	5	zwitterionic	2.5	-0.28	train
Dimetindene	5636-83-9	C=1(c2c(cccc2)CC1CCN(C)C)[C@@H](c1ccccn1)C	2.16	4.83		5.98	4.6	Arnera, V.; Wermeille, M.; Wellman, M.; Llull, J. B.; Althaus, M. A.; Balant, L. P. Pharmacokinetics of dimetindene after intravenous and oral administration to healthy volunteers. Arzneimittel-Forschung, 1990, 40, 1346-1348.	Data digitized from plot. AUCinf calculated within 2% of reported AUCinf. N=8, 4 mg dose, 75 kg median weight taken from reported range.		1960	292.42	2	0	16.1	5	cationic	4.0	2.5	train
Roflumilast	162401-32-3	C(=O)(c1ccc(c(c1)OCC1CC1)OC(F)F)Nc1c(cncc1Cl)Cl	1.92	2.2	0.01	14.5	15.1	High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast T.D. Bethke and G. Lahu. Int. J.of Clin. Pharmacol. and Therapeutics, 2011,  49, 51-57.	 Calculated from digitized plot. Median weight 75kg. Reported AUC(-inf)= 14.1 ug*h/L.Calculated AUC 15.1 ng*h/mL. 150 ug dose, N=12.		1995	403.21	5	1	60.4	7	neutral	3.5	3.5	train
Propafenone	54063-53-5	CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2	2.2	16.0	0.0379999999999999	2.2	2.1	Arboix M, Puigdemont A, Moya A, and Cinca J (1985) Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia.  Meth. Find. Exptl. Clin. Pharmacol. 7: 436-438.  Hollmann M, Brode E, Hotz D, Kaumeier S, and Kerhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man.  Arzn. Forsch. 33: 763-770.  Chan GLY, Axelson JE, Price JDE, McErlane KM, and Kerr CR (1989) In vitro protein binding of propafenone in normal and uremic human sera.  Eur. J. Clin. Pharmacol. 36: 495-499.  Tonn GR, Kerr CR, and Axelson JE (1992) In vitro protein binding of propafenone and 5-hydroxypropafenone in serum, in solutions of isolated serum proteins, and to red blood cells. J. Pharm. Sci. 81: 1098-1103.	VDss calculated from analysis of the C vs t data provided in the reference by Arboix, et al and Hollmann et al..		1961	341.44	4	2	58.6	11	cationic	3.3	1.5	test
Lidocaine	137-58-6	CCN(CC)CC(=O)Nc1c(C)cccc1C	1.8	16.0	0.33	1.9	1.6	Bauer LA, Brown T, Gilbaldi M, Hudson L, Nelson S, Raisys V, and Shea JP (1982) Influence of long-term infusions on lidocaine kinetics.  Clin. Pharmacol. Ther. 31: 433-437.  Bennett PN, Aarons LJ, Bending MR, Steiner JA, and Rowland M (1982) Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependecy studies in man.  J. Pharmacokinet. Biopharm. 10: 265-281.  Grossman SH, Davis D, Kitchell BB, Shand DG, and Routledge PA (1982) Diazepam and lidocaine plasma protein binding in renal disease.  Clin. Pharmacol. Ther. 31: 350-357.  Barry M, Keeling PW, Weir D, and Feely J (1990) Severity of cirrhosis and the relationship of alpha 1-acid glycoprotein concentration to plasma protein binding of lidocaine.  Clin. Pharmacol. Ther.  47: 366-370.	Lignocaine. Maricaine.		1946	234.34	3	1	32.3	5	cationic	2.7	2.0	train
Alpiropride	81982-32-3	C1C[N@@]([C@@H](C1)CNC(c1c(cc(c(c1)S(NC)(=O)=O)N)OC)=O)CC=C	2.3	5.47		7.0	4.8	 F. BRESSOLLE, J. BRES and M. SNOUSSI. High-performance liquid chromatographic determination of a new benzamide in biological fluids for use in a human pharmacokinetic study. Journal of Chromatography, Biomedical Applications  1985 343, 443-448	Reported as Riv 2093. N=12, 50 mg dose. 67 kg weight calculated from VDss (L/kg), clearance (L/h) and MRT.		1982	382.48	8	3	113.8	8	cationic	0.97	-0.1	train
Dinaciclib	779353-01-4	c1(cc(nc2n1ncc2CC)N1[C@@H](CCCC1)CCO)NCc1cn(=O)ccc1	0.32	4.65		1.1	2.1	John J Nemunaitis, Karen A Small, Paul Kirschmeier, Da Zhang, Yali Zhu, Ying-Ming Jou, Paul Statkevich, Siu-Long Yao and Rajat Bannerji. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. Journal of Translational Medicine 2013, 11:259 (page1-14)	Data digitized from plot reported and compared to AUC in supplementary information. Day 1, 12 mg/m2, N=11. AUC(inf) 92% of reported. 70 kg weight assumed.		2004	396.49	8	2	88.7	7	neutral	0.88	0.88	train
Melphalan	148-82-3	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(=O)O	0.48	7.0	0.14	1.1	1.0	Woodhouse KW, Hamilton P, Lennard A, and Rawlins MD (1983) The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dosing regimen.  Eur. J. Clin. Pharmacol. 24: 283-285.  Hersh MR, Ludden TM, Kuhn JG, and Knight WA (1983) Pharmacokinetics of high dose melphalan.  Invest. New Drugs. 1: 331-334.  Gera S, Musch E, Osterheld HKO, and Loos U (1989) Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.  Canc. Chemother. Pharmacol. 23: 76-80.  Grieg NH, Sweeney DJ, and Rapoport SI (1987) Melphalan concentration dependent protein binding in healthy humans and rats.  Eur. J. Clin. Pharmacol. 32: 179-185.			1946	305.2	4	2	66.6	8	zwitterionic	2.0	0.36	train
TAS-106	180300-43-0	[C@H]1(n2c(=O)nc(cc2)N)O[C@@H]([C@]([C@H]1O)(O)C#C)CO	1.1	1.6		11.7	10.9	A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of TAS-106 Once per Week for Three Consecutive Weeks Every 28 Days in Patients with Solid Tumors. BENJAMIN FRIDAY, YVONNE LASSERE, CHRISTINA A. MEYERS,.AKIRA MITA, JAMES L. ABBRUZZESE and MELANIE B. THOMAS. Anticancer Res. 2012, 32,1689-1695.	3'-c-Ethynylcytidine. Ecyd. Weighted average of 15 subjects. Doses of 0.33 to 2.64 mg/m2 across 15 subjects in total. Data reported corrected for weight. 		1996	267.24	8	4	130.8	3	neutral	-3.2	-3.2	train
Carprofen	53716-49-7	CC(c1ccc2c3cc(ccc3[nH]c2c1)Cl)C(=O)O	0.22	0.51	0.001	7.2	9.9	Crevoisier C. Pharmacokinetc properties of carprofen in humans.  Eur J Rheumatol Inflamm. 1982, 5: 492-502	RO 20-5720. Rimadyl. MRT from VDss and clearance.		1974	273.71	3	2	53.1	2	anionic	4.0	0.95	train
Otamixaban	193153-04-7	[H]/N=C(/c1cccc(c1)C[C@H]([C@@H](C)NC(=O)c2ccc(cc2)c3cc[n+](cc3)[O-])C(=O)OC)\N	0.89	7.38		2.02	3.0	Anne Paccaly, PharmD, Annke Frick, PhD, Shashank Rohatagi, PhD, Jingli Liu, PhD, Umesh Shukla, PhD, Ronald Rosenburg, MD, Markus Hinder, MD, and Bradford K. Jensen, PhD. Pharmacokinetics of Otamixaban, a Direct FactorXa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure. J Clin Pharmacol 2006;46:37-44.	From reference. Vdss values ranged from 35 (16) to 90 (25) L in the 6-hour infusion study and from 136 (81) to 202 (43) L in the 24-hour infusion study. Vdss values tended to decrease as the infusion rate increased. Median value of 62.5 L The mean (CV%) total plasma Cl ranged from 20 (21) to 42 (17) L/h in the 6-hour infusion study and from 29 (32) to 36 (25) L/h in the 24-hour infusion study and tended to decrease as the infusion rate increased. Median taken as 31 L/h. All data taken from 6-hour infusion across 0.04 to 1.1 mg/kg. Linear PK. 70 kg body weight assumed. N=6 for each dose. MRT from VDss and clearance. t1/2 highly dependent on sampling times post end of infusion. Tken as 3 hours from 6 hr infusion to 12 hrs total sampling.		1997	446.5	8	3	132.2	9	cationic	0.89	-0.91	train
RGB-286638	784210-88-4	N(C(=O)NN1CCOCC1)c1c2C(=O)c3c([nH]nc3c3ccc(cc3)CN3CCN(CC3)CCOC)c2ccc1	5.9	11.5		8.5	9.9	Diane A.J. van der Biessen, Herman Burger, Peter de Bruijn, Cor H.J. Lamers, Nicole Naus, Hannes Loferer, Erik A.C. Wiemer, Ron H.J. Mathijssen, Maja J.A. de Jonge.  Phase I study of RGB-286638, a novel, multi-targeted cyclin-dependent kinase inhibitor in patients with solid tumors. Clin Cancer Res 2014 20(18); 4776–83	Data  digitized from plot for 1 representative subject at 80mg dose.  Linear PK from 20 mg/d to 160 mg/d on day 1. Well within range in Table 4 and accepted. 70 kg average weight assumed.  SMILES and CAS number corresponding to free base. Dihydrochloride salt CAS # 784210-87-3. Reported data at 80 mg/d clearance 12.3 mL/min/kg,  and t1/2 9.1 hr. 		2004	545.63	11	3	115.1	8	cationic	0.95	0.41	train
Scutellarin	27740-01-8	c1cc(ccc1c2cc(=O)c3c(o2)cc(c(c3O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O	0.88	46.58	0.1	0.31	1.18	Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325.//ppb: Huang, Yong; Chen, Hui; Zheng, Lin; He, Feng; Zhang, Zhirong; Wang, Yonglin . Determination of plasma protein binding rates of protocatechuic acid, isoorientin and scutellarin in Compound Hongcao freeze-​dried powder for injection by ultrafiltration combined with UPLC-​ESI-​MS​/MS. Zhongguo Yaoxue Zazhi (Beijing, China). 2011, 46, 1200-1204.	Data digitized from plot reported.  All from average males/females. 6 vials EH product tested for content via HPLC. 37.2 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.		1889	462.36	12	7	207.6	4	anionic	0.29	-4.5	train
Lormetazepam	848-75-9	CN1C(=O)C(O)N=C(c2ccccc2Cl)c3cc(Cl)ccc13	1.6	4.0	0.12	6.7	4.9	Humpel M, Illi V, Milius W, Wendt H, and Kurowski M (1979) The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. Eur. J. Drug Metab. Pharmacokinet. 4: 237-243.	Pharmacokinetic parameters were calculated from C vs t obtained by digitization of the plot included in the reference.		1963	335.18	4	1	52.9	1	neutral	2.8	2.8	test
Heroin	561-27-3	CC(=O)Oc1ccc2c3c1O[C@@H]4[C@]35CC[N@@]([C@H](C2)[C@@H]5C=C[C@@H]4OC(=O)C)C	1.31	212.3		0.1	0.062	Elisabeth J. Rook, Jan M. van Ree, Wim van den Brink, Michel J. X. Hillebrand, Alwin D. R. Huitema, Vincent M. Hendriks, Jos H. Beijnen. Pharmacokinetics and Pharmacodynamics of High Doses of Pharmaceutically Prepared Heroin, by Intravenous or by Inhalation Route in Opioid-Dependent Patients. Basic & Clinical Pharmacology & Toxicology 2006, 98, 86–96.	"N=11, 73 kg average weight reported. No actual dose reported. 930 L/h average clearance at ""steady-state"" after iv doses to ""chasers"" and VD as 96 L but without specification of type of volume. VD taken as Vbeta = VDss as seemingly showing  1 compartment behavior. T1/2 of terminal phase: 3.7 minutes. MRT = t1/2/0.693."		1906	369.41	6	0	65.1	4	cationic	1.9	1.1	train
Y 20811	107433-19-2	Cc1ccc(cc1C(c2c(cc(cc2C)C(=O)O)C)O)n3ccnc3	0.37	2.91		2.17	2.37	Mitsutaka Kanamaru,  Mitsuyoshi Nakashima. Phase I Study of Y-20811, a New Long- Acting Thromboxane Synthetase Inhibitor by Intravenous Administration. J ClIn Pharmacol 1989;29: 563-567 	N=6 for each dose. 5, 10 and 25 mg doses. Data averaged across doses. 62.7 kg average weight. MRT from VDss and clearance.	SMILES and CAS # referring to free acid but dosed as sodium salt.	1986	336.38	5	2	75.3	4	anionic	3.6	1.2	train
Nemonoxacin	378746-64-6	C(C(=C(N1C2CC2)C(=C2N(C[C@](C[C@]3([H])C)(N)[H])C3)OC)C=C2)(C(=C1)C(O)=O)=O	1.9	3.8	0.84	8.4	13.5	Cao Guo-Ying; Zhang Jing; Zhang Ying-Yuan; Guo Bei-Ning; Yu Ji-Cheng; Wu Xiao-Jie; Chen Yuan-Cheng; Shi Yao-Guo; Wu Ju-Fang . Safety, Tolerability, and Pharmacokinetics of Intravenous Nemonoxacin in Healthy Chinese Volunteers. Antimicrobial agents and chemotherapy. 2014 ; 58, 6116-6121; . ppb: Luke Lin, Li-Wen Chang, Cheng-Yuan Tsai, Ching-Hung Hsu, David T. Chung, William S. Aronstein, Funmi Ajayi, Barbara Kuzmak, and Robert A. LyonDose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Nemonoxacin (TG-873870), aNovel Potent Broad-Spectrum Nonfluorinated Quinolone, in Healthy Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,  2010, 54, 405–410	TG-873870. Average of N=35 across 250, 500 and 750 mg dose. Data from table 4. Infusion 45', 90 and 135', respectively. 59 kg average body weight reported.		2001	371.43	7	2	96.1	4	zwitterionic	2.5	0.077	train
Apixaban	503612-47-3	N1(CCc2c(C1=O)n(nc2C(=O)N)c1ccc(cc1)OC)c1ccc(cc1)N1CCCCC1=O	0.3	0.8	0.13		12.0	FDA aproval data. Accessed through PharmaPendium on June 23 2014.https://www.pharmapendium.com/fda.do?document=a9a1a313612e0fc9f6473123da9f3f58&drugName=Apixaban&reference=32clearance  3.43 L/h and t1/2 12 h. 70 kg assumed. VDss 21 L.	Assumed 70 kg as average weight. 		2003	459.5	9	1	110.8	5	neutral	2.5	2.5	train
Forodesine	209799-67-7	[nH]1cnc2c([nH]cc2[C@@H]2N[C@@H]([C@H]([C@H]2O)O)CO)c1=O		1.56			11.6	A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)Varsha Gandhi, John M. Kilpatrick, William Plunkett, Mary Ayres, Leigh Harman, Min Du, Shanta Bantia, Jan Davisson, William G. Wierda, Stefan Faderl, Hagop Kantarjian, and Deborah Thomas. BLOOD, 2005   VOLUME 106, (13)4253-4260.	Only Vz reported. Infusion across 5 patients. One patient received 4 doses. N = 8 total. 		1998	266.25	8	6	134.3	2	cationic	-3.9	-4.3	train
Penciclovir	39809-25-1	NC1=NC(=O)c2ncn(CCC(CO)CO)c2N1	1.1	8.4	0.84	2.4	2.1	Fowles SF, Pierce DM, Prince WT, and Staniforth D (1992) The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects.  Eur. J. Clin. Pharmacol. 43: 513-516.  Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, Prince WT, and Ramji JV (1994) Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects.  Xenobiotica 24: 357-368.	Parameters calculated from digitized plots and averaged over all dose levels.		1972	253.26	8	4	125.8	5	neutral	-1.6	-1.6	train
Metopimazine	14008-44-7	CS(=O)(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN4CCC(CC4)C(=O)N		12.14			4.0	GAILLOT J , LE ROUX Y, COURNOT A. , DUCHIER J. , FRYDMAN A. PHARMACOKINETICS OF HETOPIMAZINE AFTER SINGLE AND REPEATED ORALADMINISTRATION IN YOUNG HEALTHY SUBJECTS.	Vogalene. 10 mg iv dose. N=12, 70 kg average weight assumed. VD (beta) reported as 300 L.		1960	445.6	6	1	83.7	6	cationic	2.5	0.91	train
Alfuzosin	81403-80-7	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C3CCCO3	1.5	5.9	0.14	4.2	4.8	Guinebault P, Colafranceschi C, Bianchetti G, Thenot JP, Maillard D, Thiercelin JF, Larribaud J, and Morselli PL (1984) Absolute bioavailability of alfuzosin, a new α1-​post synaptic receptor antagonist, after oral and intravenous administration.  Biopharm. Pharmacokinet. 2nd European Congress 2: 578-583. ppb: The PDR states: Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL). Median value taken. Accessed January 7 2015. http://www.pdr3d.com/detail.php?c=76486#section-13.	VDss calculated from C vs t data obtained by digitization of the plots included in the reference.		1982	389.45	9	2	111.8	8	cationic	2.3	1.8	train
Thioguanine	154-42-7	n1c2c(nc[nH]2)c([nH]c1N)=S	2.89	15.4		3.13	24.35	 Kitchen, Brenda J.; Balis, Frank M.; Poplack, David G.; O'brien, Michelle; Craig, Catherine E.; Adamson, Peter C.  A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clinical Cancer Research, 1997, 3, 713-717.	2-amino-6-mercaptopurine. 6-mercaptoguanine. Data digitized from plot 20 mg/m2/h, 24 hr infusion. N=13. 70 kg average weight assumed. 1.73 m2/70 kg conversion factor used. Reported clearance 608 mL/min/m2 corresponding to 15.02 mL/min/kg.		1948	167.19	5	3	83.4	0	anionic	-1.2	-4.7	train
Chlorambucil	305-03-3	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	0.26	2.8	0.01	1.5	1.1	Newell DR, Calvert AH, Harrap KR, and McElwain TJ (1983) Studies on the pharmacokinetics of chlorambucil and prednimustine in man.  Br. J. Clin. Pharmacol. 15: 253-258.   Leukeran Product Label.	VDss calculated from C vs t data obtained by digitization of plots provided in the reference for two subjects administered a 10 mg dose.		1953	304.21	3	1	40.5	9	anionic	3.8	1.2	train
Pitavastatin	147511-69-1	c12ccccc1c(c(c(n2)C1CC1)\C=C\[C@H](C[C@H](CC(=O)O)O)O)c1ccc(cc1)F	0.9	5.85	0.005	2.7	4.6	Pitavastatin Calcium - FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 022363/S-000 Part 01. Accessed via Pharmapendium.	Followed as acid. VDss from MRT and clearance. Vd reported as 148.1 L. N=18, 2 mg dose, 70 kg weight assumed.		1997	421.46	5	3	90.6	8	anionic	3.9	0.54	test
SarCNU	81965-43-7	CN(CC(=O)N)C(=O)N(CCCl)N=O	0.76	9.0		1.4	1.0	Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH, Batist G, Patenaudr F, Bangash N, Panarello L, Alaoui-Jamali M, and Sausville E (2003) SarCNU, a nitosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.  J. Clin. Oncol. 21: 232-240.	VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.		1982	222.63	7	1	96.1	5	neutral	-0.4	-0.4	train
Laniquidar	197509-46-9	COC(c1cnc2C(=C3CCN(CC3)CCc3ccc(cc3)OCc3ccc4ccccc4n3)c3ccccc3CCn12)=O	6.03	14.14	0.001	7.1	10.6	De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780. 	70 kg average weight assumed.  MRT calculated from CL and VDss. 50 mg iv dose		1997	584.71	7	0	69.5	8	cationic	7.4	6.8	train
Iomeprol	78649-41-9	[H]N(C[C@@H](CO[H])O[H])C(c1c(c(C(N([H])C[C@@H](CO[H])O[H])=O)c(c(c1I)N(C)C(CO[H])=O)I)I)=O	0.23	1.4	1.0	2.7	2.3	Lorusso et al. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal imperiment or end-stage renal disease requiring hemodyalisis. Invest. Radiol. 2001, 36, 309-316. ppb: Rosati G. Clinical pharmacology of iomeprol. European journal of  1994, 18 Suppl 1 S51-60	Only data in healthy volunteers taken. N=6. 50 ml of 400 mg I/mL solution of iomeprol.		1981	777.09	11	7	179.7	15	neutral	-2.1	-2.1	train
Voriconazole	137234-62-9	C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F	2.2	8.3	0.42	4.4	5.6	Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, and Nichols D (2003) The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.  Br. J. Clin. Pharmacol. 56(Suppl. 1):  2-9.   Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, Smith DA, Walker DK, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.  Drug Metab. Dispos. 31: 731-741.			1991	349.31	6	1	76.7	5	neutral	1.5	1.5	train
Docetaxel	114977-28-5	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6)C(=C([C@@H](O)C3=O)C5(C)C)C	2.1	14.0	0.04	2.5	11.0	Rosing H, Lustig V, van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, Schellens JHM, Rodenhuis S, Bult A, and Beijnen JH (2000) Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.    Cancer Chemother. Pharmacol. 45: 213-218.  Minami H, Kawada K, Sasaki Y, Igarashi T, Saeki T, Tahara M, Itoh K, and Fujii H (2006) Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients.  Cancer Sci.  97: 235-241.			1988	807.88	15	5	224.4	12	neutral	3.0	3.0	train
Penclomedine	108030-77-9	c1(c(c(c(Cl)c(n1)OC)OC)Cl)C(Cl)(Cl)Cl	9.1	29.9		5.1	3.8	Phase I and Pharmacologic Study of Penclomedine,a Novel Alkylating Agent, in Patients With Solid Tumors Seamus O'Reilly, Louise B. Grochow, Ross C. Donehower, Tian-Ling Chen, Katherine Bowling, Neil R. Hartman,Robert F. Struck, and Eric K. Rowinsky. Journal of Clinical Oncology, 1997, Vol 15 1974-1984.	70 kg assumed. Average from Table 6. Data from day 1 taken. Day 5 very similar. N=6, 5 mg/kg 5 minutes infusion. 75.3 kg average weight. 45  to 550 mg/m2/day doses. 		1987	325.4	3	0	31.3	2	neutral	4.4	4.4	train
Butylbiguanide	692-13-7	CCCCNC(=N)NC(=N)N	1.84	6.58	0.9	4.66	4.62	Lintz, W.; Berger, W.; Aenishaenslin, W.; Kutova, V.; Baerlocher, Ch.; Kapp, J. P.; Beckmann, R. Butylbiguanide concentration in plasma, liver, and intestine after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. (1974), 7(6), 433-48.	N=4, diabetic patients, 77 kg average weight reported, 50 mg dose i.v. VDss from V1 and k12, k21. MRT from VDss and clearance. Renal clearance 73%. Total radioactivity but noted that there is no metabolism by the authors so that the equivalence radiioactivity=compound is valid. 		1959	157.22	5	5	97.8	6	cationic	-0.61	-4.1	train
Tiopronin	1953-02-2	C[C@@H](C(NCC(O)=O)=O)S	1.39	1.48	0.45	15.7	55.0	M. S. Carlsson , T. Denneberg  , B.-M. Emanuelsson , B. Kagedal , and S. Lindgren. Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. Eur J Clin Pharmacol (1990) 38:499-503. fu from clearance total and unbound reported. M. S. Carlsson , T. Denneberg  , B.-M. Emanuelsson , B. Kagedal , and S. Lindgren. Pharmacokinetics of oral tiopronin Eur J Clin Pharmacol (1993) 45:79-84. Data initially and erroneously entered from this work being a follow-up p.o. of 1990 work. Corrected on January 6 2015.	2-MPG. N=10, 71 kg average weight. 250 mg iv dose.	Almost exclusively excreted unchanged renally. As reported by Carlsson et al.	1963	163.19	4	2	66.4	3	anionic	-0.23	-3.6	test
Demethylchlortetracycline	127-33-3	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N	1.3	1.1	0.59	17.0	12.0	Kunin, CM, Darnbush AC, and Finland M. Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest. 1959, 38, 1950-63.	Calculated from digitized plots 		1957	464.85	10	6	181.6	2	anionic	-0.19	-2.9	train
Colchicine	64-86-8	COC1=CC=C2C(=CC1=O)[C@H](CCc3cc(OC)c(OC)c(OC)c23)NC(=O)C	6.1	2.1	0.61	49.0	58.0	Ferron GM, Rochdi M, Jusko WJ, and Scherrmann JM (1996) Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36: 874-883.  Sabouraud A, Chappey O, Dupin T, and Scherrmann JM (1994)  Binding of colchicine and thiocolchicoside to human serum proteins and blood cells.  Int. J. Clin. Pharmacol. Ther. 32: 429-432.			1971	399.44	7	1	83.1	5	neutral	1.1	1.1	test
Delafloxacin	189279-58-1	c1c2c(c(c(c1F)N3CC(C3)O)Cl)n(cc(c2=O)C(=O)O)c4c(cc(c(n4)N)F)F	0.35	2.33	0.16	2.5	2.1	Randall Hoover; Thomas Hunt; Michael Benedict; Susan K. Paulson; Laura Lawrence; Sue Cammarata and Eugene Sun. Safety, Tolerability,and Pharmacokinetic Properties ofIntravenous Delafloxacin After Single and Multiple Dosesin Healthy Volunteers. Clin. Ther. 2016, 38, 53-65. // ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf.	Data digitized from plot reported at 750 mg dose, 1-hr iv infusion,  N=8, 73.8 kg as average weight reported across entire cohort. T1/2 taken as very long in report but concentration at < 2% of Cmax after 12 hours. Extrapolation using 3-12 hr interval (5 points). AUCinf reported 74.4 ug.hr.mL-1 and calculated as 72.2 ug.hr.mL-1 (3% deviation). Clearance not linear across entire range and a mid point (750 mg) was chosen from range of 300 to 1200 mg.  35% excreted unchanged renally.		1997	440.76	8	3	121.7	3	anionic	2.5	-0.0083	train
Esmolol	81147-92-4	COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1	1.2	290.0	0.59	0.07	0.15	Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, and Lai CM (1983) Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin. Pharmacol. Ther. 34: 427-434.  Okamura M, Kumagai M, Murasaki Y, Ohkura T, Miyamoto Y, Kawai Y, Tamura T, Takariki Y, and Tomisawa H (2001) Stereoselective pharmacokinetics of esmolol enantiomers.  Yakubutsu Dotai 16: 427-435.			1981	295.37	5	2	67.8	10	cationic	2.0	0.18	train
16-acetyl gitoxin	7242-07-1	C1([C@@H]2[C@@]3([C@@]([C@@H]4[C@@H]([C@@]5(CC[C@@H](O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O)C[C@@H]5CC4)C)CC3)(C[C@@H]2OC(=O)C)O)C)=CC(=O)OC1	0.78	0.18	0.07	72.3	51.6	Hausten, K.-O. On the Pharmacokinetics of 16-Acetyl-gitoxin and Its Bioavailability from Pengitoxin-Containing Tablet Formulations. Int. J. Pharmacokin. Biopharm. 1986, 14, 357-364. 	16-O-acetylgitoxin. N=6, 65.3 kg average weight. 0.5 mg administered iv in 1 minute. MRT calculate from AUC and AUMC in turn calculated from C1, C2 and lamba 1 and 2. VDss then calculated from MRT and clearance reported. Fu reported by the author from own previous work. G. Hiiller, K.-O. Haustein, and D. Murawski. On the plasma-protein binding of 16-acetylgitoxin.Int. J. Clin. Pharmacol. 19:200-202 (1981).		1960	822.98	15	5	209.1	9	neutral	0.93	0.93	train
Clomipramine	303-49-1	CN(C)CCCN1c2ccccc2CCc3ccc(Cl)cc13	13.0	8.2	0.029	26.0	26.0	Ollagnier M, Pellet J, Gay JP, Lang F, Ouvry MC, and Blanchon Y (1984) Pharmacocinetique d'une dose unique de clomipramine, en intraveneuse, chez le voluntaire sain.  Therapie  39: 237-245.  Nyberg G and Maartensson E (1984)  Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.	Pharmacokinetic parameters were calculated from C vs t provided in the reference. 		1961	314.85	2	0	6.5	4	cationic	5.1	3.4	test
Tebufelone	112018-00-5	[H]C#CCCCC(c1cc(c(c(c1)C(C)(C)C)O[H])C(C)(C)C)=O	12.0	8.9		22.3	50.7	Cruze CA, Kelm GR, Meredith MP (1995) Interspecies scaling of tebufelone pharmacokinetic data and application to preclinical toxicology. Pharm. Res. 12, 895-901.	Data digitized from Dedrick-like plot reported. AUC reported 579 ng.h.mL-1; clearance reported 9.87 mL.min-1.kg-1.  These data refer to the corrected t and C data for human. 25 mg dose and 72.9 average weight.		1987	300.44	2	1	37.3	6	neutral	5.4	5.4	train
Trospium	47608-32-2	c1ccc(cc1)C(c2ccccc2)(C(=O)O[C@@H]3C[C@@H]4CCC(C3)[N+]45CCCC5)O	5.1	13.9	0.33	6.1	5.0	Trospium Chloride - FDA Approval Package. Clinical Pharmacology and Biopharmaceutics Review 021595/S-000 Part 03. Accessed via Pharmapendium. Ppb: the PDR states: Protein binding ranged from 50 to 85% when concentration levels of trospium chloride (0.5 to 50 ng/mL) were incubated with human serum in vitro.  Accessed January 6 2015. http://pdr3d.com/detail.php?c=104533#section-13. Median value of 67% taken.	Structure and smiles refer to cation. 70 kg assumed. MRT reported. Ppb reported as range between 50 and 85%.	72% of dose elininated in urine, of which 80% is unchanged. ~ 60% total unchanged. Trospium Chloride - FDA Approval PackageClinical Pharmacology and Biopharmaceutics Review 021595/S-000 Part 03. Accessed via Pharmapendium.	1997	392.51	4	1	46.5	5	neutral	0.83	0.83	train
Methotrexate	59-05-2	CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O	0.43	2.1	0.37	3.4	3.9	Bore P, Bruno R, Lena N, Favre R, and Cano JP (1987) Methotrexate and 7-hydroxymethotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate.  Eur. J. Canc. Clin. Oncol. 23: 1385-1390.  Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, and Furst DE (1989) Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.  J. Pharm. Sci. 78: 165-171.  Esposito M, Rosso R, and Santi L (1974) Plasma protein binding of antineoplastic drugs in rats and humans.  IRCS Library Compendium 2: 1180.			1948	454.44	13	5	210.5	9	anionic	-0.25	-6.4	test
Telcagepant	781649-09-0	O=c1n(c2c([nH]1)nccc2)C1CCN(CC1)C(=O)N[C@H]1C(=O)N(CC(F)(F)F)C[C@@H](CC1)c1c(F)c(F)ccc1	0.86	5.8		2.5	8.2	The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects. Tae H. Han, Rebecca L. Blanchard,  John Palcza,  Ashley Martucci, Cynthia M. Miller-Stein,  Maria Gutierrez, Deborah Panebianco, Ronda K. Rippley,  Christopher Lines,  and M. Gail Murphy. Arch Drug Info 2010,3:55–62	MK-0974. 70 kg average weight assumed. Weighted average across all 7 doses from 5 mg to  250 mg (N=10 for each one).  t1/2 calculated only from 4 doses from 50 to 250 MRT calculated from VD and CLMicrodose?		2004	566.52	9	2	103.3	4	neutral	3.5	-0.022	train
Viqualine	72714-74-0	c12c(ccc(c2)OC)nccc1CCC[C@@H]1[C@@H](CNCC1)C=C	24.4	26.0		15.6	12.1	J. B. Fourtillan, S. Bouquet, J. Girault, M. A. Lefebvre, C. Maulet, Ph. Courtois. Pharmacokinetics and bioavailability of viqualine a new antidepressant. European Journal of Drug Metabolism and Pharmacokinetics. 1985, 10(1) , 3-10	Mean BW = 64.8 kg (N=5), 25 mg infusion dose. 		1979	310.43	3	1	34.1	6	cationic	4.3	2.0	test
Casopitant	414910-27-3	c1(cc(cc(c1)[C@H](N(C(=O)N1CC[C@@H](C[C@@H]1c1c(cc(cc1)F)C)N1CCN(CC1)C(=O)C)C)C)C(F)(F)F)C(F)(F)F	2.77	3.07	1.0	15.04	15.6	Mario Pellegatti, Ellenia Bordini, Patrizia Fizzotti, Andy Roberts, and Brendan M. Johnson. Disposition and Metabolism of Radiolabeled Casopitant in Humans. Drug Metab. Disp. 2009, 37, 1635-1645.// ppb: Bauman, John W.; Antal, Joyce M.; Adams, Laurel M.; Johnson, Brendan M.; Murray, Sharon C.; Peng, Bin; Kirby, Lyndon C.; Lebowitz, Peter F.; Marbury, Thomas C.; Swan, Suzanne; Gutierrez, Maria. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-​1 receptor antagonist. Invest. New Drugs, 2012, 30, 662–671.	70 kg average weight assumed. N=6. 15 minutes infusion of a 90 mg dose. MRT from VDss and clearance.		2002	616.61	6	0	47.1	4	neutral	5.4	5.4	test
Cyclophosphamide	50-18-0	ClCCN(CCCl)P1(=O)NCCCO1	0.73	1.1	0.87	11.0	8.0	Juma FD, Rogers HJ, and Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br. J. Clin. Pharmacol. 8: 209-217.  Juma FD, Rogers HJ, and Trounce JR (1979) The kinetics of salivary elimination of cyclophosphamide in man.  Br. J. Clin. Pharmacol. 8: 455-458.	VDss calculated from microconstants reported in the reference.		1946	261.09	4	1	41.6	5	neutral	0.79	0.55	train
Sulfamethoxazole	723-46-6	Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1	0.3	0.36	0.23	14.0	9.8	Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299.			1957	253.28	6	2	98.5	3	anionic	1.1	-0.56	train
Cefprozil	92665-29-7	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C2=O)C(=O)O	0.21	2.9	0.59	1.2	1.2	Shyu WC, Shah VR, Campbell DA, Wilber RB, Pittman KA, and Barbhaiya RH (1992) Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J. Clin. Pharm. 32: 798-803.  Shyu WC, Shukla UA, Shah VR, Papp EA, and Barbhaiya RH (1991)  Simultaneous high-performance liquid chromatographic analysis of cefprozil diastereomers in a pharmacokinetic study.  Pharm. Res.  8: 992-996.	Racemate data		1984	389.43	8	4	133.0	5	zwitterionic	-0.39	-1.8	test
Metrizoate	1949-45-7	CN(C(=O)C)c1c(I)c(NC(=O)C)c(I)c(C(=O)O)c1I	0.17	2.7	1.0	1.0	1.3	Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.	VDss calculated from C vs t data obtained by digitization of the plot provided in the reference. CAS number and structure refer to the free acid.		1962	627.94	6	2	86.7	3	anionic	1.4	-1.9	train
Cimetropium	150521-16-7	C[N+]1([C@@H]2C[C@H](C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)c4ccccc4)CC5CC5	1.12	25.0		0.74	0.83	B. P. IMBIMBO, S. DANIOTTI, A. VIDI, D. FOSCHI, F . SAPORITI,  L. FERRANTE. Discontinuous Oral Absorption of Cimetropium Bromide, a New Antispasmodic Drug. J. Pharm. Sci. 1986, 75, 680-684. 	N=8, 10 mg dose. Clearance reported in table III. MRT calculated from AUC and AUMC in turn calculated from A, B, α and β. VDss obtained from MRT and clearance. T1/2 reported.	46% excreted unchanged in urine.	1973	358.45	5	1	59.1	7	neutral	-2.8	-2.8	train
Cannabinol	521-35-7	c12c3c(OC(c1ccc(c2)C)(C)C)cc(CCCCC)cc3O	16.98	17.85		15.86	25.51	Eva Johansson, Agneta Ohlsson, Jan-Erik Lindgren, Stig Agurell, Hampton Gillespie, Leo E. Hollister. Single-dose Kinetics of Deuterium-labelled Cannabinol in Man After Intravenous Administration and Smoking. BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1987, 14, 495-499	DEUTERATED COMPOUND. Calculation performed from data reported in Table. AUC inf reported within 3% of calculated. N=6, 20 mg dose, 72.2 kg average weight.		1896	310.43	2	1	29.5	4	neutral	6.7	6.7	train
Flupirtine	56995-20-1	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	1.1	1.6	0.15	11.0	8.5	Hlavica VP and Niebch G (1985) Untersuchungen zur pharmakokinetik und biotransformation des analgetikums flupirtin beim menschen.  Arz. Forsch. 35: 67-74. 	VDss calculated from C vs t data obtained by digitization of the plots in the reference.		1979	304.32	6	3	89.3	6	cationic	3.1	2.7	train
Pelrinone	94386-65-9	[H]N(Cc1cccnc1)C1=C(C#N)C(N=C(C)N1[H])=O	0.39	5.8	0.05	1.1	0.95	Scatina, J. A.; Hicks, D. R.; Kraml, M.; Cayen, M. N. Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man Eur. J. Drug Metab. Pharmacokin. 1990, 15, 37-48.	 N=4, 67 Kg average weight, 0.149 mg/Kg iv dose		1985	241.25	6	2	90.2	4	neutral	-0.75	-0.8	train
Didanosine	69655-05-6	OC[C@@H]1CC[C@@H](O1)n2cnc3C(=O)NC=Nc23	0.77	11.0	0.95	1.2	1.4	Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, Pittman KA, and Barbhaiya RH (1991) Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.  Clin. Pharmacol. Ther. 49: 523-535.  Videx Product Label.	2',3'-Dideoxyinosine, NSC612049		1979	236.23	7	2	88.7	2	neutral	-0.93	-0.95	train
Carzelesin	119813-10-4	c1(N(CC)CC)cc2oc(C(Nc3ccc4c(c3)cc([nH]4)C(N3C[C@H](c4c5c([nH]cc5C)c(OC(=O)Nc5ccccc5)cc34)CCl)=O)=O)cc2cc1	0.09	2.9		0.51	0.48	Data as average of two different single patient profiles (N=2):   (1) Van Tellingen, Olaf; Nooijen, Willem J.; Schaaf, Larry J.; Van Der Valk, Martin; Van Asperen, Judith; Henrar, Roland E. C.; Beijnen, Jos H. Comparative pharmacology of the novel cyclopropylpyrroloindole-​prodrug carzelesin in mice, rats, and humans. Cancer Research (1998), 58(11), 2410-2416.     (2) van Tellingen O, Punt CJ, Awada A, Wagener DJ, Piccart MJ, Groot Y, Schaaf LJ, Henrar RE, Nooijen WJ, Beijnen JH. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother Pharmacol. 1998;41(5):377–384.	 (1) data digitized from Fig. 4.  Dose 300 ug/m2 (0.0075 mg/kg), infusion T=10 min, N=1*. (2) data digitized from Fig. 5 (dose 210 ug/m2 (0.00525 mg/kg), infusion T=10 min, N=1**.* reported data: see Table 4 (data seems to be for 3 patients (N=3) presented in Table 1 in van Tellingen O. et al, Cancer Chemother Pharmacol, 1998, 41, 377-384). The actual digitized values (AUC, CL, ...) seem to agree with the values reported for the last patient in Table 1.** 48th patient in Table 1, reported data: see Table 1 where the AUC, CL, half times, ... for all patients are reported (CL = 0.29 L/h/kg)		1988	729.22	11	4	136.0	10	neutral	7.7	7.7	train
Naphtidrofuryl oxalate	31329-57-4	CCN(CC)CCOC(=O)C(Cc1cccc2c1cccc2)CC3CCCO3	0.98	10.8	0.2	1.5	1.35	RYUICHIRO NISHIGAKI, KOSHIRO UMEMURA, KIYOSHI OKUI, TOSHIHIRO HAYASHI, TERUO YAMAMOTO, and YUJI SAKURAI. The Pharmacokinetical Analysis of the Fate of Naphtidrofuryl Oxalate (LS121) in Human Subjects. I. Single Intravenous Infusion and Multiple Intravenous Infusion. YAKUGAKU ZASSHI, 106(10)906-915(1986).//ppb: David R Goldsmith, Keri Wellington. Naphtidofuryl. Drugs and Aging, 2005, 22, 967-977.	Data also available in tabular form (Cp vs. time). Structure refers to free base. LS121 as oxalate, LS84 as free base. N=16 (across two doses), 65 kg average reported. VDss from V1 and k12 and k21. 120 and 200 mg 2 hr infusion. Table V. MRT from clearance and VDss and t1/2 from 0.693beta.//Review article citing ppb taken from another review article.		1964	383.52	4	0	38.8	11	cationic	4.9	3.6	test
Flavopiridol	146426-40-6	CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccccc4Cl	1.5	6.1	0.06	4.0	5.2	Zhai S Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo AJ, Melillo G, Fuse E, and Figg WD (2003) Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.  Anti-Cancer Drugs. 14: 125-135.  Rudek MA, Bauer KS, Lush RM, Stinson SF,  Senderowicz AM, Headlee DJ, Arbuck SG,  Cox MC, Murgo AJ, Sausville EA, and Figg WD (2003) Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.  Ann. Pharmacother. 37: 1369-1374. 			1961	401.84	6	3	90.2	2	zwitterionic	3.6	2.4	test
Lurtotecan	149882-10-0	CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5cc6c(cc5c4CN7CCN(CC7)C)OCCO6)O	4.77	25.07		3.5	3.54	CJH Gerrits, GJ Creemers, JHM Schellens, P Wissel, AS Th Planting, R Kunka, K Selinger,M de Boer-Dennert, Y Marijnen, M Harteveld, J Verweij. Phase I and pharmacological study of the new topoisomerase I inhibitor G1147211, using a daily x 5 intravenous administration. British Journal of Cancer (1996) 73, 744-750.	GG211 or GI147211. NX211. Quantitation of lactone form. Weight averaged value across several doses, from Table IV (Day 1). N=17 overall. 1.73m2/70 kg factor used.		1993	518.56	10	1	106.4	3	cationic	1.0	-0.084	train
Traxoprodil	134234-12-1	C[C@@H]([C@@H](O)c1ccc(O)cc1)N2CCC(O)(CC2)c3ccccc3	4.4	27.0	0.63	2.6	3.7	Taylor TJ, Diringer K, Russell T, Venkatakrishnan K, Wilner K, Crownover PH, Benincosa LJ, and Gibbs MA (2006) Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolizers.  Clin. Pharmacokin. 45: 989-1001.  	Data from CYP2D6 extensive metabolizers.		1990	327.42	4	3	63.9	4	cationic	2.1	1.0	test
Baclofen	1134-47-0	c1cc(ccc1C(CC(=O)O)CN)C	0.65	1.7	0.69	6.36	5.24	Suresh K. Agarwal, Robert L. Kriel, James C. Cloyd, Lisa D. Coles, Lisa A. Scherkenbach, Michael H. Tobin and Linda E. Krach. Pilot Study Assessing Pharmacokinetics and Tolerability of Oral and Intravenous Baclofen in Healthy Adult Volunteers. J Child Neurol published online 14 July 2014. DOI: 10.1177/0883073814535504. ppb (UF method): Wuis EW, Dirks MJ, Termond EF, Vree TB, Van der Kleijn E. 1989. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol 37:181–184.	N=12, digitized from plot reported. 5 mg dose. 70 kg average weight assumed. 		1962	193.24	3	2	63.3	4	zwitterionic	1.1	-1.2	train
Imipramine	50-49-7	CN(C)CCCN1c2ccccc2CCc3ccccc13	12.0	13.0	0.0749999999999999	15.0	16.0	Brosen K and Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.  Clin. Pharmacol. Ther.  43: 400-406.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.   Danon A and Chen Z (1979) Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia.  Clin. Pharmacol. Ther. 25: 316-321.	VDss was calculated using C vs t data obtained from plots provided in the reference.		1959	280.41	2	0	6.5	4	cationic	4.3	2.7	train
Oxybutynin	5633-20-5	CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2	0.85	5.1	0.0033999999999999	2.7	7.2	Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, and Herchuelz A (1988) The pharmacokinetics of oxybutynin in man.  Eur. J. Clin. Pharmacol. 35: 515-520.  Mizushima H, Takanaka K, Abe K, Fukazawa I, and Ishizuka H (2007) Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica 37: 59-73.	Parameters calculated from C vs t data obtained by digitization of the plot provided in the reference.  Used data from 1 mg dose.		1964	357.49	4	1	49.8	10	cationic	4.3	3.9	train
Eletriptan	143322-58-1	CN1CCC[C@@H]1Cc2c[nH]c3ccc(CCS(=O)(=O)c4ccccc4)cc23	1.6	5.3	0.15	5.0	4.2	Milton AK, Scott NR, Allen MJ, Abel S, Jenkins VC, James GC, Rance DJ, and Eve MD (2002) Pharmacokinetics, pharmacodynamics, and safety of the 5-HT1B/1D agonist eletriptan following intravenous and oral administration.  J. Clin. Pharmacol. 42: 528-539.  Relpax Product Label.	VDss was calculated from C vs t data obtained by digitization of the plot (0.102 mg/kg dose only) included in the reference.		1992	382.52	4	1	53.2	6	cationic	3.7	2.2	train
Itraconazole	84625-61-6	CCC(C)N1N=CN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(OCC5COC(Cn6cncn6)(O5)c7ccc(Cl)cc7Cl)cc4	7.4	5.1	0.002	24.0	25.0	Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, and Cauwenbergh G (1989) The clinical pharmacokinetics of itraconazole: an overview.  Mycoses  32(Suppl 1): 67-87.  	VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.		1983	705.63	12	0	100.8	11	neutral	5.8	5.8	test
Temoporfin	122341-38-2	c1(c2[nH]c(c(c3nc(c(c4cc(ccc4)O)c4[nH]c(c(c5nc1CC5)c1cc(ccc1)O)cc4)C=C3)c1cc(ccc1)O)cc2)c1cc(ccc1)O		0.06	0.14		91.5	Temoporfin - EMA Approval PackageScientific Discussion. Accessedd through Pharmapendium.	average of two studies at 0.15 mg/kg in healthy volunteers. VD reported as 0.39 and 0.46 L/kg, without definition and likely to be VDz.	Metabolic pthway not identified. EMA Package	1989	690.83	8	8	136.6	4	neutral	5.1	5.0	train
Piperacillin	61477-96-1	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4ccccc4)C(=O)C1=O	0.27	4.0	0.5	1.1	0.96	De Schepper PJ, Tjandramaga TB, Mullie A, Verbesselt R, van Hecken A, Verberckmoes R, and Verbist L (1982) Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure.  J. Antimic. Chemother. 9(Suppl B) 49-57. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, and Verbist L (1978) Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.  Antimic. Agents Chemother. 14: 829-837.   Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.			1977	517.55	12	3	156.4	6	anionic	0.84	-2.5	train
Risperidone	106266-06-2	CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1	1.1	5.4	0.1	3.4	3.2	Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, and Jonkman JHG (1993)  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.  Clin. Pharmacol. Ther.  54: 257-268.  Mannens G, Meuldermans W, Snoeck E, and Heykants J (1994) Plasma protein binding of risperidone and its distribution in blood.    Psychopharmacology 114: 566-572.	CYP2D6 EM data only.		1986	410.48	6	0	62.2	4	cationic	3.1	2.6	train
Belinostat	414864-00-9	c1c(cccc1\C=C\C(NO)=O)S(=O)(=O)Nc1ccccc1	0.8	23.6	0.06	0.6	1.6	U Lassen, LR Molife, M Sorensen, S-A Engelholm, L Vidal, R Sinha, RT Penson, P Buhl-Jensen, E Crowley, J Tjornelund, P Knoblauch,  JS de Bono. Phase I trial of belinostat with carboplatin and/or paclitaxel. British Journal of Cancer (2010) 103, 12 – 17. ppb: The PDR states: In vitro plasma studies have shown that between 92.9% and 95.8% of belinostat is bound to protein in an equilibrium dialysis assay, and was independent of belinostat plasma concentrations from 500 to 25,000 ng/mL. 94% taken as median. Accessed January 7 2015. http://www.pdr3d.com/detail.php?c=126664#section-12	Belinostrat administrated in combination with carboplatin and/or paclitaxel. MRT calculated form VDss and CL. VDss and CL corrected with 1.73 m2/70 kg body surface/body weight factor. (see table II in ref. cited). N=30 (23 patients. For 7of them day 1 and day 3 PK profiles are available) 		2002	318.35	6	3	95.5	5	neutral	1.5	1.4	test
Ondansetron	99614-02-5	Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C	1.8	5.8	0.27	5.2	3.4	Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, and Powell JR (1992) Age and gender effects on ondansetron pharmacokinetics:  evaluation of healthy aged volunteers.  Clin. Pharmacol. Ther. 51: 51-55..  Zofran Product Label.			1985	293.36	4	0	39.8	2	cationic	2.1	1.0	train
Pinocembrin	480-39-7	c1ccc([C@H]2Oc3cc(O)cc(c3C(C2)=O)O)cc1	0.8	27.0		0.47	0.7	Determination of pinocembrin in human plasma by solid-phase extraction and LC/MS/MS: application to pharmacokinetic studies Bei Yan, Guoying Cao, Taohua Sun, Xi Zhao, Xin Hu, Jiling Yan, Yueying Peng, Aixin Shi, Yang Li, Wei Xue, Min Lia, Kexin Li*and Yingfa Liu*. Biomedical Chromatography, April 2014. (wileyonlinelibrary.com) DOI 10.1002/bmc.3186.	Digitized from plot reported. 30 minutes infusion, 20 mg, N=8, 70 kg average weight assumed.data in very good agreement with reported values in table.		1928	256.25	4	2	66.8	1	neutral	2.5	2.3	test
Cefixime	79350-37-1	Nc1nc(cs1)\C(=N\OCC(=O)O)\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C	0.24	1.0	0.31	3.9	3.2	Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AI, Yacobi A, and Silber BM (1988) Absolute bioavailability of cefixime in man.  J. Clin. Pharmacol. 28: 700-706. 			1981	453.45	12	4	184.5	8	anionic	-0.38	-6.7	train
Bizelesin	129655-21-6	c12c(N(C(c3cc4cc(NC(Nc5cc6c([nH]c(c6)C(N6c7c(c8c([nH]cc8C)c(c7)O)[C@@H](C6)CCl)=O)cc5)=O)ccc4[nH]3)=O)C[C@H]2CCl)cc(O)c2c1c(c[nH]2)C	0.05	0.5		1.7	1.6	Pitot, Henry C.; Reid, Joel M.; Sloan, Jeff A.; Ames, Matthew M.; Adjei, Alex A.; Rubin, Joseph; Bagniewski, Pamela G.; Atherton, Pamela; Rayson, Daniel; Goldberg, Richard M; Erlichman, Charles. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin. Cancer Res. 2002, 8, 712-717.	Weighted average over 17 patients with doses ranging from 0.1 ug/m2 to 1 ug/m2.  1.73m2/70 kg conversion factor used.		1990	815.7	13	8	185.4	6	neutral	5.9	5.9	train
1,3-DCQA	19870-46-3	O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c3ccc(O)c(O)c3)C(=O)O	0.79	8.7		1.5	1.37	Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325	1,3-dicaffeoylquinic acid. Data digitized from plot reported. All from average males/females. 6 vials EH product tested for content via HPLC. 1.26 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.		1964	516.45	12	7	211.3	9	anionic	2.1	-1.6	train
Asenapine	65576-45-6	c12c(cccc1)Oc1ccc(cc1[C@@H]1[C@@H]2CN(C1)C)Cl	23.0	12.4	0.05	30.9		PDR. Accessed February 18 2013. http://www.pdr3d.com/detail.php?c=82606#section-14	SAPHRIS. Asenapine is a high clearance drug with a clearance after intravenous administration of 52 L/h. VDss 20-25 L/kg. 95% bound. 70 kg assumed.no t1/2 reported. MRT from VDss and clearance. 		1985	285.77	2	0	12.5	0	cationic	4.7	3.1	train
Oxytetracycline	79-57-2	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)C(=O)c4c(O)cccc4[C@@]3(C)O	1.7	2.0	0.9	12.0	10.0	Kunin CM, Darnbush AC, and Finland M (1959) Distribution and excretion of four tetracycline analogs in normal young men.  J. Clin. Invest.  38  1950-1963.	calculated from digitized plots 		1948	460.43	11	7	201.8	2	zwitterionic	-1.9	-4.3	test
Chlorthalidone	77-36-1	NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23	3.9	1.5	0.24	43.0	36.0	Fleuren HLJ, Thien TA, Verwey-van Wissen CPW, and von Rossum JM (1979) Absolute bioavailability of chlorthalidone in man: a cross over study after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 15: 35-50.  Dieterle W, Wagner J, and Faigle JW (1976)  Binding of chlorthalidone (Hygroton) to blood components in man.  Eur. J. Clin. Pharmacol. 10: 37-42.			1959	338.77	6	3	109.5	2	neutral	0.85	0.84	test
Fenoldopam	67227-56-9	c12[C@@H](c3ccc(O)cc3)CNCCc1c(c(O)c(c2)O)Cl	0.5	41.5	0.12	0.2	1.0	PP. Fenoldopam Mesylate - FDA Approval PackageClinical Pharmacology and Biopharmaceutics Review 019922 1997-Sep-25  PDF(1763k)	N=12 healthy volunteers. 1 ug/kg/min dose. MRT from VDss and clearance.	PP. Fenoldopam Mesylate - FDA Approval PackageClinical Pharmacology and Biopharmaceutics Review 019922 1997-Sep-25  PDF(1763k)	1980	305.76	4	4	72.7	1	cationic	2.7	1.9	train
Doxapram	309-29-5	CCN1CC(CCN2CCOCC2)C(C1=O)(c3ccccc3)c4ccccc4	1.2	5.3		3.7	4.1	Robson RH and Prescott LF (1978) A pharmacokinetic study of doxapram in patients and volunteers.  Br. J. Clin. Pharmacol. 7: 81-87.  	VDss calculated from digitized from plot reported		1963	378.51	4	0	32.8	6	neutral	3.2	3.1	train
Ticarcillin	34787-01-4	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O	0.16	1.8	0.55	1.5	1.0	Watanabe K, Koyama M, Iijima F, Nakazawa H, and Nakahira K (1986) Phase I studies on BRL 28500 (clavulanic acid-ticarcillin).  Chemotherapy 34: 247.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.  Libke RD, Clarke JT, Ralph ED, Luthy RP, and Kirby WMM (1975) Ticarcillin vs carbenicillin: clinical pharmacokinetics.  Clin. Pharmacol. Ther.  17: 441-446.	Combined data from Watanabe and Libke papers		1972	384.43	8	3	124.0	5	anionic	0.88	-5.7	train
CDK-712	626252-75-3	C([C@H]1c2c(cc(c(c2)O)O)CCN1)c1c2c(ccc1)cccc2	1.09	156.0		0.12	1.58	Sang-In Park,JaeWoo Kim, Kyung-Sang Yu, In-Jin Jang, SeungHwan Lee. Changes in Cardiac Function After a Single Intravenous Administration of CKD-712 in Healthy Male Volunteers. Clin Drug Investig 2017 37, 393–403.	Data digitized from plot reported in SI. 160 ug/kg dose, N=6, 1 h infusion. Generally linear except a deviation at 320 ug/kg dose. Starting dose 20 ug/kg. AUC0-inf reported as 16.40 ug.h.L-1. AUC0-inf calculated as 17.09 ug.h.L-1. 4% difference.		2003	305.37	3	3	52.5	2	cationic	3.7	2.6	train
Pazopanib	4731-52-6	Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C	0.16	0.06	0.01	44.4		Pazopanib Hydrochloride - EMA Approval Package. Accessed through Pharmapendium.	70 kg assumed and MRT from VDss and clearance. The mean half-life after a single dose of 800 mg was30.9 ±4 hours (VEG10003). This value is from an oral dose.		2002	437.52	9	2	119.0	5	neutral	4.0	4.0	train
Olprinone	106730-54-5	c1(c(cc(c(=O)[nH]1)C#N)c1ccc2n(c1)ccn2)C	0.64	11.0		0.97	1.13	QIN Yong-ping，MIAO Jia，MEI Ya-jun, WANG Ying，NAN Feng，ZHU Xiao-hong, XIANG Jin，SHU Shi-qing，YU Qin，LI Mei，LIANG Mao-zhi. Pharmacokinetic study of olprinone hydrochloride injection in healthy volunteers. Chinese Journal of New Drugs 2015, 24(12), 1397-1403. 	Abstract in English. Article in Chinese. Seemingly 62% excreted unchanged in urine. VDss from clearance and MRTinf reported. Very tight data with N=9 across three doses (averaged) at 5, 10 and 20 ug/kg injected in 5 minutes.		1986	250.26	5	1	74.0	2	neutral	0.59	-2.9	train
XK469R	157435-10-4	CC(C(=O)O)Oc1ccc(cc1)Oc2cnc3ccc(cc3n2)Cl	0.19	0.05	0.0035999999999999	63.0	48.2	Wendy Stock,  Samir D. Undevia, Carol Bivins, Farhad Ravandi, Olatoyosi Odenike, Stefan Faderl, Elizabeth Rich, Gautam Borthakur, Lucy Godley, Srdan Verstovsek , Andrew Artz , William Wierda, Richard A. Larson, Yanming Zhang,  Jorge Cortes, Mark J. Ratain, Francis J. Giles. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. // ppb: Alousi AM1, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase II beta inhibitor. Invest. New Drugs, 2007, 25, 147-154.	Weight averaged across 4 doses (1400 to 2750 mg) average weight assumed to be 70 kg. MRT from clearance and VDss. Both CAS number and smiles refer to free acid		1994	344.75	6	1	81.5	5	anionic	4.0	0.79	train
Desferrioxamine	70-51-9	C(CCC(NCCCCCN(C(C)=O)O)=O)(N(CCCCCNC(CCC(N(CCCCCN)O)=O)=O)O)=O	1.35	8.33		2.7	3.05	P. LEE, N. MOHAMMED, L. MARSHALL, A. D. ABEYSINGHE, A. C. HIDER, J. B. PORTER, AND S. SINGH. INTRAVENOUS INFUSION PHARMACOKINETICS OF DESFERRIOXAMINE INTHALASSAEMIC PATIENTS. Drug Metab. Disp. 1993, 21, 640-644.	Deferoxamine. EC 200-738-5. N=11, clearance as dose over AUC appears to be correct. Dose 50 mg/kg/24hr over 48 hours. MRT appears a bit smaller than when calculated from reported AUMC, AUC and clearance. AUC0-inf 354 umol.h.L-1; AUMC0-inf  9170 umol.h2.L-1. All data taken as is from paper. MW 560.69		1960	560.68	14	6	205.8	23	cationic	-2.6	-5.8	train
Salvianolic acid B	121521-90-2	c1cc(c(cc1C[C@H](C(=O)O)OC(=O)/C=C/c2ccc(c3c2[C@@H]([C@H](O3)c4ccc(c(c4)O)O)C(=O)OC(Cc5ccc(c(c5)O)O)C(=O)O)O)O)O	0.14	7.17	0.08	0.42	0.29	Xiuxue Li , Chen Cheng , Fengqing Wang , Yühong Huang , Weiwei Jia , Olajide E. Olaleye ,Meijuan Li , Yanfen Li , Chuan Li. Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine. Drug Metab. Pharmacokin. 2015. http://dx.doi.org/10.1016/j.dmpk.2015.10.005//ppb: Yuan, Hai-jian; An, Yi-qiang; Chen, Yi-gang . Determination of protein binding rates of salvianolic acid B and danshensu with different plasmas. Zhongguo Shiyan Fangjixue Zazhi. 2014, 20, 136-139.	3 different dosage regimens to 6 M and 6 F each. (three different infusions). Actual doses not reported. Standardized solution? Data averaged across all patients (N=36). Reported to be eliminated by bile after methylation in rat.		1981	718.61	16	9	278.0	14	anionic	3.7	-3.1	train
Pancuronium	15500-66-0	CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(=O)C)[N+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1[N+]6(C)CCCCC6	0.2	1.5	0.09	2.2	1.9	Caldwell JE, Castagnoli KP, Canfell PC, Fahey MR, Lynam DP, Fisher DM, and Miller RD (1988) Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action.  Br. J. Anaesth. 61:  693-697.  Wood M, Stone WJ, and Wood AJJ (1983)  Plasma binding of pancuronium:  effects of age, sex, and disease.  Anesth. Analg.  62: 29-32			1966	572.86	6	0	52.6	6	neutral	-0.36	-0.36	train
Flunisolide	3385-03-3	O1[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@@]5(C)[C@H]4[C@H](C[C@@]3([C@]2(C(CO)=O)OC1(C)C)C)O	1.08	9.5	0.24	1.89	1.68	Flunisolide metabolism and dynamics of a metabolite.Chaplin MD, Rooks W II, Swenson EW, Cooper WC, Nerenberg C and Chu NI. Clin Pharmacol Ther 1980, 27:402-413.//ppb: Loren M. Berry, Chao Li, and Zhiyang Zhao. Species Differences in Distribution and Prediction of Human Vss from Preclinical Data Drug Metab. Disp. 2011, 39, 2103-2106.	N=9, 1 mg dose. Calculated from reported plot (figure 3) in blood corrected for B/P =0.89. Data in blood and 0.89 B/P reported. Table involving 12 subjects (median weight 81.8 kg) but plot referring to 9 of them. The calculations below were performed after a correction to yield plasma concentration and some adjustment of time points digitized to approach reported AUC (C0 inserted manually). Reported blood AUC for N=12 17.64 hr*ng/mL corresponding to 19.82 hr*ng/mL. 8% difference from computed values.  		1963	434.5	6	2	93.1	2	neutral	2.5	2.5	train
Isavuconazole	241479-67-4	[H]O[C@](Cn1cncn1)(c1cc(ccc1F)F)[C@@H](C)c1nc(cs1)c1ccc(C#N)cc1	5.37	0.85	0.01	105.5	86.9	Schmitt-Hoffmann A. et al. Single-​ascending-​dose pharmacokinetics and safety of the novel broad-​spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrobial Agents and Chemotherapy, 2006, 50(1), 279-285. //ppb: Robert W. Townsend,corresponding author1 Shahzad Akhtar,1 Harry Alcorn, Jolene K. Berg, Donna L. Kowalski, Salim Mujais, and Amit V. Desai. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017, 73, 669–678.	PK profiles refer to BAL4815 after iv infusion of prodrug BAL8557. BAL4815 = IsavuconazoleData from 50,100,200 mg equivalents of BAL4815 iv infusion (1 h) dose of prodrug BAL8557, N=18, 77.1(SD 10.4) average weight (57-100Kg). t½ taken as the β phase		1999	437.47	6	1	87.6	8	neutral	4.0	4.0	train
Biricodar	159997-94-1	N1([C@@H](CCCC1)C(=O)OC(CCCc1cnccc1)CCCc1cnccc1)C(=O)C(c1cc(c(c(c1)OC)OC)OC)=O	1.34	8.5		2.62	1.1	Ronald A. Peck, Jan Hewett, Matthew W. Harding, Yow-Ming Wang, Pravin R. Chaturvedi, Anish Bhatnagar,Harvey Ziessman, Frank Atkins, and Michael J. Hawkins. Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin. Journal of Clinical Oncology,  2001, Vol 19, 3130-3141	VX-710 COMBINED DATA FROM TABLE 6. MRT from VDss and ClearanceThere were no differences in VX-710 pharmacokinetic parameter values between the VX-710 single-agent infusion cycle and the combination therapy cycle (VX-710–doxorubicin), as shown in Fig 3, where selected pharmacokinetic parameters of VX-710 from all patients were plotted by cohorts. VX-710 has linear pharmacokinetics as indicated by the lack of dose dependence in CLs and Vss. In lieu of the observed linear pharmacokinetics, Table 6 summarizes the pharmacokinetic parameters of VX-710 for the combined data from all dose groups and both treatment phases, except for Css, which was proportional to dose and hence summarized by dose cohorts.		1994	603.71	10	0	117.1	16	neutral	5.4	5.4	test
CGP31608	107740-67-0	C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)CN)C(=O)O)O	0.23	7.67		0.5	0.5	R. Wise, J. M. Webberky, J. M. Andrews and J. P. Asbby. The pharmacokinetics and tissue penetration of intravenously administered CGP 31608. Journal of Antimicrobial Chemotherapy (1988) 21, 85-91	Data digitzed from plot reported. 1 g administered to N=6 volunteers in 1 hr infusion. 82.2 kg average weight. Calculated AUCinf essentially identical to reported value.		1985	244.27	6	3	103.9	3	zwitterionic	-2.4	-4.7	test
Pentoxifylline	6493-05-6	CN1C(=O)N(CCCCC(=O)C)C(=O)c2c1ncn2C	1.8	39.0	0.51	0.77	1.2	Beermann B, Ings R, Mansby J, Chamberlain J, and McDonald A (1985) Kinetics of intravenous and oral pentoxifylline in healthy subjects.  Clin. Pharmacol. Ther. 37: 25-28.  Rames A, Poirier JM, LeCoz F, Midavaine M, Lecocq B, Grange JD, Poupon R, Cheymol G, and Jaillon P (1990) Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.  Clin. Pharmacol. Ther. 47: 354-359.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191	Calculated VDss from C vs t data obtained by digitization of plots included in the references. 		1959	278.31	7	0	75.5	5	neutral	0.65	0.65	train
Flecainide	54143-55-4	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2	6.1	4.9	0.52	21.0	12.0	Wang T, Siddoway LA, Thompson KA, Conard GJ, Bergstrand RH, Kvam D, Roden DM, and Woosley RL (1988) The development and testing of intravenous dosing regimens: application to flecainide for teh suppression of ventricular arrhythmias.  Clin. Pharmacol. Ther. 43: 499-508.  Tjandra-Maga TB, Verbesselt R, Van Hecken A, Mullie A, and DeSchepper PJ (1986) Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man.  Br. J. Clin. Pharmacol. 22: 309-316.  Munafo A, Buchlin T, Tuto D, and Biollaz J (1992) The effect of low dose quinidine on the disposition of flecainide in healthy volunteers.  Eur. J. Clin. Pharmacol. 43: 441-443.  Johnston A, Muhiddin KA, and Hamer J (1982) Serum protein binding of flecainide.  Br. J. Clin. Pharmacol. 13: 606P.	VDss from the reference by Wang, et al, was calculated using the compartmental parameters reported in the reference.		1979	414.34	5	2	59.6	7	cationic	3.1	1.6	train
Vortioxetine	508233-74-7	CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1	35.3	5.8	0.02	101.0	72.0	Johan Areberg, Birgitte Søgaard and Astrid-Maria Højer. The Clinical Pharmacokinetics of Lu AA21004 and its Major Metabolite in Healthy Young Volunteers Basic & Clinical Pharmacology & Toxicology, 2012, 111, 198–205. ppb: the PDR states: The plasma protein binding of vortioxetine in humans is 98%, independent of plasma concentrations. Accessed January 5 2015. http://www.pdr3d.com/detail.php?c=131238#section-15	 Lu AA21004. Brintellix. Trintellix. AUCinf reported as 376 hr*ng/mL, clearance 26 L/h (5.8 mL/min/kg).  75 kg median weight reported, 10 mg dose over 6 hours infusion. N=22.		2003	298.45	2	1	15.3	3	cationic	4.8	3.1	test
OGT719	185843-61-2	O[C@H]1[C@@H](O[C@@H]([C@@H]([C@@H]1O)O)CO)n1c(=O)[nH]c(=O)c(c1)F	0.33	1.38		3.95	4.21	Sharma, Ricky A.; Eatock, Martin M.; Twelves, Christopher J.; Brown, Gill; McLelland, Heather R.; Clayton, Kathryn T.; O'Byrne, Kenneth J.; Moyses, Chris; Carmichael, James; Steward, William P.  Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Chemother. Pharmacol. 2001, 48, 197-201.	OGT719 Data digitized from plot reported by  Sharma et al. 250 mg/m2. N=16, 1.73 m2/70kg conversion factor.  85% reported excreted unchenged in urine.		1996	292.22	9	5	145.0	2	neutral	-3.1	-6.6	train
Glufosfamide	132682-98-5	P(O[C@H]1[C@@H]([C@H]([C@H](O)[C@H](O1)CO)O)O)(=O)(NCCCl)NCCCl	0.24	1.6	0.71	2.49	2.37	 Data (N=13, doses 3200-6000 mg/m2 6h i.v. infusion) reported in Table 5 in Shimizu, Toshio; Okamoto, Isamu; Tamura, Kenji; Satoh, Taroh; Miyazaki, Masaki; Akashi, Yusaku; Ozaki, Tomohiro; Fukuoka, Masahiro; Nakagawa, Kazuhiko.  Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors.    Cancer Chemotherapy and Pharmacology  (2010),  65(2),  243-250.  MRT calculated from CL and VDss.      fu as average of all human serum and human plasma measures reported in Table 4 in Stueben, Joerg; Port, Ruediger; Bertram, Barbara; Bollow, Ursula; Hull, William E.; Schaper, Marianne; Pohl, Joerg; Wiessler, Manfred.  Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent .beta.-D-glucosylisophosporamide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.    Cancer Chemotherapy and Pharmacology  (1996),  38(4),  355-365.	Data as weighted average of three doses across 13 patients (3,200/4,500/6000 mg/m2, N-3/7/3). Conversion factor used 1.73m2/70 kg. 6-hour infusion. Also reported as D 19575 		1990	383.16	9	6	140.5	9	neutral	-2.3	-2.3	train
Pipemidic acid	51940-44-4	c12c(c(c(C(O)=O)cn1CC)=O)cnc(n2)N1CCNCC1	0.88	2.84	0.7	5.15	3.69	R. CADORNIGA, S. NEGRO, I. MOLINA, J. A. GUTIERREZ. Estudio farmacocinetico del acido pipemidico trihidrato despues de su administracion en perfusion. An. Real Acad. Farm. 1987,53: 585-595//ppb: Shimizu M, Nakamura S, Takase Y, Kurobe N. Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother. 1975, 7,441-446.	N=5, 67 kg average weight, 300 mg dose 20' infusion.		1974	303.32	8	2	100.3	3	zwitterionic	0.63	-1.9	train
Tocainide	41708-72-9	CC(N)C(=O)Nc1c(C)cccc1C	1.8	2.2	0.87	14.0	12.0	Lalka D, Meyer MB, Duce BR, and Elvin AT (1976) Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.  Clin. Pharmacol. Ther. 19: 757-766.  Thomson AH, Murdoch G, Pottage A, Kelman AW, Whiting B, and Hillis WS (1986) The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.  Br. J. Clin. Pharmacol. 21: 149-154,  Sedman AJ, Bloedow DC, and Gal J (1982) Serum binding of tocainide and its enantiomers in human subjects.  Res. Comm. Chem Path. Pharmacol. 38: 165-168.	Combined data from individual enantiomers.		1973	192.26	3	2	55.1	2	cationic	0.65	0.27	train
Alcuronium	23214-96-2	OC\C=C/1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C5=CN6[C@H]7C(=CN([C@H]35)c8ccccc48)[C@H]9C[C@H]%10[C@@]7(CC[N@@+]%10(CC=C)C/C/9=C/CO)c%11ccccc6%11	0.32	1.3		4.1	3.6	Walker J, Shanks CA, and Triggs EJ (1980)  Clinical pharmacokinetics of alcuronium chloride in man.  Eur. J. Clin. Pharmacol. 17: 449-457. 			1960	666.89	6	2	46.9	6	neutral	-4.8	-4.8	train
Gavestinel	153436-22-7	[H]N(C(C=Cc1c2c(cc(cc2n([H])c1C(=O)O[H])[Cl])[Cl])=O)c1ccccc1	0.12	0.089	0.002	22.47		Iavarone L et al. First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol, 1999, 39, 560-566. 	Data from 100 mg iv dose, 70 Kg weight. MRT calculated from CL and VDss. GV150526. fu reported as fu% but unlikely to be %.  Likely to be fu.		1993	375.21	5	3	82.2	5	anionic	4.6	1.8	train
AMP579	213453-89-5	CC[C@H](Cc1c(ccs1)Cl)Nc2c3ccn(c3ncn2)[C@@H]4C[C@@H]([C@H]([C@H]4O)O)C(=O)NCC	0.84	12.0	0.03	1.18	1.33	Peter N. Zannikos, PharmD, PhD, Bradford K. Jensen, PhD, Bruno X. Boutouyrie, MD,Lisa Tripp, BS, Luo Yongyi, MS, Tracy McGowan, MD, Scott A. Waldman, MD, PhD,and Howard E. Greenberg, MD, MS. Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End-Stage Renal Insufficiency. Journal of Clinical Pharmacology, 2000;40:745-751	Data taken from Table II. N=6, healthy volunteers, 50 ug/kg as a 6-hour infusion. MRT from clearance and VDss. Seemingly no significant difference with renally impaired patients.		1998	478.01	8	4	112.3	8	neutral	2.6	2.6	train
Moexipril 	103775-10-6	C(c1ccccc1)C[C@H](N[C@H](C(N1Cc2c(C[C@H]1C(O)=O)cc(OC)c(c2)OC)=O)C)C(OCC)=O		6.3	0.12		1.3	Moexipril Hydrochloride - FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020312 Part 01. Package accessed through Pharmapendium. March 7 2013.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-312_Moexipril_Univasc.pdf. Accessed June 27 2017.	VD reported in PDR as about 183 liters, but not specified as VDss or VDz. Likely to be latter. 70 kg assumed as average weight. Accessed March 7 2013.//ppb: data from young subjects. Bining in elderly subjects ~ 48%.	excreted in feces and urine (mostly urine) as moexiprilat (diacid). See label of FDA review package.	1958	498.57	9	2	114.4	12	anionic	3.0	-0.37	train
CB 10-277	7203-91-0	CN(C)N=Nc1ccc(cc1)C(=O)O	0.25	1.3		3.0	2.5	Foster BJ, Newell DR, Carmichael J, Harris AL, Gumbrell LA, Jones M, Goodard PM, and Calvert AH (1993) Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.  Br. J. Canc. 67: 362-368.	Parameters were calculated using C vs t data obtained by digitzation of the plot provided in the reference.		1965	193.2	5	1	65.3	3	anionic	2.5	-0.32	train
BB 83698	325795-25-3	CC(C)(C)[C@H](NC(=O)[C@H](CC1CCCC1)CN(O)C=O)C(=O)N2CCN(Cc3ccc4OCOc4c3)CC2	1.1	3.1	0.2	5.9	9.4	Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, and Johnson KW. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimic. Agents Chemother. (2004)  48: 4835-4842.			2001	530.66	10	2	111.6	9	neutral	2.1	2.1	test
Nifedipine	21829-25-4	COC(=O)C1=C(C)NC(=C(C1c2ccccc2N(=O)=O)C(=O)OC)C	0.79	7.3	0.0439999999999999	1.8	1.9	Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, and George CF (1995) Factors affecting the absolute bioavailability of nifedipine.  Br. J. Clin. Pharmacol. 40: 51-58.  Robertson DRC, Waller DG, Renwick AG, and George CF (1988) Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.  Br. J. Clin. Pharmacol. 25: 297-305.  Kleinbloesem CH, van Harten J, Wilson JPH, Danhof M, van Brummelen P, and Breimer DD (1986) Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin. Pharmacol. Ther. 40: 21-28.  Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, and Breimer DD (1984) Nifedipine: kinetics and dynamics in healthy subjects.  Clin. Pharmacol. Ther. 35: 742-749.    Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.  			1974	346.33	8	1	110.4	6	neutral	2.4	2.4	train
Foscarnet	4428-95-9	OC(=O)P(=O)(O)O	0.5	2.1	0.85	4.0	4.7	Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, and Jacobson MA (1995) Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.    Clin. Pharmacol. Ther. 57: 403-412.  Sjovall J, Bergdahl S, Movin G, Ogenstad S, and Saarimaki M (1989) Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.  Antimic. Agents Chemother. 33: 1023-1031.	Long terminal phase t1/2 of 88 h reported in Sjovall with a 3-compartment model.		1924	126.01	5	3	94.8	1	anionic	-1.2	-7.6	test
Lefamulin	1061337-51-6	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O	1.32	3.96	0.17	5.53	6.4	M. Zeitlinger, R. Schwameis, A. Burian, B. Burian, P. Matzneller, M. Muller, W. W. Wicha, D. B. Strickmann and W. Prince. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother 2016; 71: 1022–1026.	Data digitized from plot reported. N=12 healthy males, 150 mg as 1-h infusion, 77.6 kg, average weight. AUC0-12 reported as 5772 ng.h.mL-1. calculated 6667 ng.h.mL-1. 15% difference.		2008	507.73	6	3	109.8	6	cationic	3.4	0.75	train
